

IDEX CORP /DE/  
Form 10-Q  
November 02, 2012  
Table of Contents

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**Form 10-Q**

**QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the quarterly period ended September 30, 2012

OR

**TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

Commission file number 1-10235

**IDEX CORPORATION**

*(Exact Name of Registrant as Specified in its Charter)*

**Delaware**  
*(State or other jurisdiction of  
incorporation or organization)*

**36-3555336**  
*(I.R.S. Employer  
Identification No.)*

**1925 West Field Court, Lake Forest, Illinois**  
*(Address of principal executive offices)*

**60045**  
*(Zip Code)*

**Registrant's telephone number: (847) 498-7070**

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes  No

## Edgar Filing: IDEX CORP /DE/ - Form 10-Q

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer  Accelerated filer  Non-accelerated filer  Smaller reporting company   
(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes  No

Number of shares of common stock of IDEX Corporation outstanding as of October 25, 2012: 82,658,275.

**Table of Contents**

**TABLE OF CONTENTS**

**Part I. Financial Information**

|         |  |    |
|---------|--|----|
| Item 1. | <u>Financial Statements</u>  | 1  |
|         | <u>Condensed Consolidated Balance Sheets</u>   | 1  |
|         | <u>Condensed Consolidated Statements of Operations</u>                                       | 2  |
|         | <u>Condensed Consolidated Statements of Comprehensive Income</u>                             | 3  |
|         | <u>Condensed Consolidated Statements of Shareholders' Equity</u>                             | 4  |
|         | <u>Condensed Consolidated Statements of Cash Flows</u>                                       | 5  |
|         | <u>Notes to Condensed Consolidated Financial Statements</u>                                  | 6  |
| Item 2. | <u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u> | 25 |
|         | <u>Cautionary Statement Under the Private Securities Litigation Reform Act</u>               | 25 |
|         | <u>Overview and Outlook</u>  | 25 |
|         | <u>Results of Operations</u>   | 26 |
|         | <u>Liquidity and Capital Resources</u>   | 32 |
| Item 3. | <u>Quantitative and Qualitative Disclosures About Market Risk</u>                            | 35 |
| Item 4. | <u>Controls and Procedures</u>   | 35 |

**Part II. Other Information**

|         |  |    |
|---------|--|----|
| Item 1. | <u>Legal Proceedings</u>   | 36 |
| Item 2. | <u>Unregistered Sales of Equity Securities and Use of Proceeds</u> | 36 |
| Item 6. | <u>Exhibits</u>  | 36 |
|         | <u>Signatures</u>  | 37 |
|         | <u>Exhibit Index</u>   | 38 |

**Table of Contents****PART I. FINANCIAL INFORMATION****Item 1. Financial Statements.**

**IDEX CORPORATION AND SUBSIDIARIES**  
**CONDENSED CONSOLIDATED BALANCE SHEETS**

(in thousands except share and per share amounts)

(unaudited)

|   | September 30, 2012 | December 31, 2011 |
|---|--------------------|-------------------|
| <b>ASSETS</b>   |                    |                   |
| Current assets  |                    |                   |
| Cash and cash equivalents   | \$ 260,503         | \$ 230,259        |
| Receivables, less allowance for doubtful accounts of \$5,858 at September 30, 2012 and \$5,860 at December 31, 2011 | 277,505            | 252,845           |
| Inventories net   | 249,564            | 254,258           |
| Other current assets  | 56,292             | 51,799            |
| Total current assets  | 843,864            | 789,161           |
| Property, plant and equipment net   | 223,762            | 213,717           |
| Goodwill  | 1,490,821          | 1,431,366         |
| Intangible assets net   | 378,660            | 382,222           |
| Other noncurrent assets   | 20,328             | 19,641            |
| Total assets  | \$ 2,957,435       | \$ 2,836,107      |
| <b>LIABILITIES AND SHAREHOLDERS' EQUITY</b>   |                    |                   |
| Current liabilities   |                    |                   |
| Trade accounts payable  | \$ 117,793         | \$ 110,977        |
| Accrued expenses  | 154,557            | 130,696           |
| Current portion of long-term debt and short-term borrowings   | 5,152              | 2,444             |
| Dividends payable   | 16,540             | 14,161            |
| Total current liabilities   | 294,042            | 258,278           |
| Long-term borrowings  | 782,768            | 806,366           |
| Deferred income taxes   | 157,971            | 142,482           |
| Other noncurrent liabilities  | 113,817            | 115,846           |
| Total liabilities   | 1,348,598          | 1,322,972         |
| Commitments and contingencies   |                    |                   |
| Shareholders' equity  |                    |                   |
| Preferred stock:  |                    |                   |
| Authorized: 5,000,000 shares, \$.01 per share par value; Issued: None   |                    |                   |
| Common stock:   |                    |                   |
| Authorized: 150,000,000 shares, \$.01 per share par value   |                    |                   |
| Issued: 87,349,352 shares at September 30, 2012 and 85,968,630 shares at December 31, 2011                          | 873                | 860               |
| Additional paid-in capital  | 536,804            | 490,128           |
| Retained earnings   | 1,249,130          | 1,142,412         |

Edgar Filing: IDEX CORP /DE/ - Form 10-Q

|  |              |              |
|--|--------------|--------------|
| Treasury stock at cost: 4,648,968 shares at September 30, 2012 and 2,734,747 shares at December 31, 2011 | (142,296)    | (64,796)     |
| Accumulated other comprehensive loss   | (35,674)     | (55,469)     |
| Total shareholders' equity   | 1,608,837    | 1,513,135    |
| Total liabilities and shareholders' equity   | \$ 2,957,435 | \$ 2,836,107 |

See Notes to Condensed Consolidated Financial Statements

**Table of Contents**

**IDEX CORPORATION AND SUBSIDIARIES**  
**CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS**

(in thousands except per share amounts)

(unaudited)

|  | Three Months Ended |            | Nine Months Ended |              |
|--|--------------------|------------|-------------------|--------------|
|  | September 30,      |            | September 30,     |              |
|  | 2012               | 2011       | 2012              | 2011         |
| Net sales  | \$ 479,859         | \$ 476,881 | \$ 1,463,420      | \$ 1,357,768 |
| Cost of sales                                      | 285,019            | 295,349    | 862,578           | 812,697      |
| Gross profit                                       | 194,840            | 181,532    | 600,842           | 545,071      |
| Selling, general and administrative expenses       | 107,167            | 107,296    | 332,431           | 313,485      |
| Restructuring expenses                             | 7,085              | 2,931      | 14,604            | 2,931        |
| Operating income                                   | 80,588             | 71,305     | 253,807           | 228,655      |
| Other income (expense) net                         | 132                | (441)      | 19                | (1,001)      |
| Interest expense                                   | 10,536             | 7,763      | 31,734            | 20,937       |
| Income before income taxes                         | 70,184             | 63,101     | 222,092           | 206,717      |
| Provision for income taxes                         | 20,057             | 14,765     | 65,443            | 60,248       |
| Net income   | \$ 50,127          | \$ 48,336  | \$ 156,649        | \$ 146,469   |
| Basic earnings per common share                    | \$ 0.60            | \$ 0.58    | \$ 1.88           | \$ 1.77      |
| Diluted earnings per common share                  | \$ 0.60            | \$ 0.58    | \$ 1.87           | \$ 1.75      |
| <i>Share data:</i>                                 |                    |            |                   |              |
| Basic weighted average common shares outstanding   | 82,482             | 82,402     | 82,820            | 81,994       |
| Diluted weighted average common shares outstanding | 83,370             | 83,586     | 83,785            | 83,533       |

See Notes to Condensed Consolidated Financial Statements

Table of Contents**IDEX CORPORATION AND SUBSIDIARIES****CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME****(in thousands)****(unaudited)**

|  | <b>Three Months Ended</b> |               | <b>Nine Months Ended</b> |                   |
|--|---------------------------|---------------|--------------------------|-------------------|
|  | <b>September 30,</b>      |               | <b>September 30,</b>     |                   |
|  | <b>2012</b>               | <b>2011</b>   | <b>2012</b>              | <b>2011</b>       |
|  | <b>(In thousands)</b>     |               |                          |                   |
| Net income   | \$ 50,127                 | \$ 48,336     | \$ 156,649               | \$ 146,469        |
| <b>Other comprehensive income</b>  |                           |               |                          |                   |
| Gains, losses and reclassification adjustments for derivatives, net of tax | 1,204                     | (22,162)      | 3,644                    | (20,398)          |
| Pension and other postretirement adjustments, net of tax                   | 1,428                     | 777           | 4,516                    | 2,354             |
| Cumulative translation adjustment  | 23,335                    | (26,437)      | 11,635                   | 5,100             |
| <b>Comprehensive income</b>  | <b>\$ 76,094</b>          | <b>\$ 514</b> | <b>\$ 176,444</b>        | <b>\$ 133,525</b> |

See Notes to Condensed Consolidated Financial Statements

**Table of Contents****IDEX CORPORATION AND SUBSIDIARIES****CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS EQUITY**

(in thousands except share amounts)

(unaudited)

|  | Accumulated Other Comprehensive<br>Income (Loss)     |                      |   |                                       |  |                   | Total<br>Shareholders<br>Equity |
|--|--|----------------------|---|---------------------------------------|--|-------------------|---------------------------------|
|  | Common<br>Stock and<br>Additional<br>Paid-In Capital | Retained<br>Earnings | Cumulative<br>Translation<br>Adjustment | Retirement<br>Benefits<br>Adjustments | Cumulative<br>Unrealized<br>Loss on<br>Derivatives | Treasury<br>Stock |                                 |
| Balance, December 31, 2011   | \$ 490,988   | \$ 1,142,412         | \$ 24,194                               | \$ (38,486)                           | \$ (41,177)  | \$ (64,796)       | \$ 1,513,135                    |
| Net income   |  | 156,649              |   |                                       |  |                   | 156,649                         |
| Cumulative translation adjustment  |  |                      | 11,635                                  |                                       |  |                   | 11,635                          |
| Pension and other postretirement<br>adjustments, net of tax  |  |                      |   | 4,516                                 |  |                   | 4,516                           |
| Amortization of forward starting swaps,<br>net of tax  |  |                      |   |                                       | 3,644  |                   | 3,644                           |
| Issuance of 1,415,457 shares of<br>common stock from issuance of<br>unvested shares, exercise of stock<br>options and deferred compensation<br>plans, net of tax benefit | 37,298   |                      |   |                                       |  |                   | 37,298                          |
| Repurchase of 1,859,611 shares of<br>common stock  |  |                      |   |                                       |  | (75,174)          | (75,174)                        |
| Unvested shares surrendered for tax<br>withholding   |  |                      |   |                                       |  | (2,326)           | (2,326)                         |
| Share-based compensation   | 9,391  |                      |   |                                       |  |                   | 9,391                           |
| Cash dividends declared \$ .60 per<br>common share   |  | (49,931)             |   |                                       |  |                   | (49,931)                        |
| Balance, September 30, 2012  | \$ 537,677   | \$ 1,249,130         | \$ 35,829                               | \$ (33,970)                           | \$ (37,533)  | \$ (142,296)      | \$ 1,608,837                    |

See Notes to Condensed Consolidated Financial Statements



**Table of Contents****IDEX CORPORATION AND SUBSIDIARIES****CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS****(in thousands)****(unaudited)**

|   | <b>Nine Months<br/>Ended September 30,</b> |             |
|---|--|-------------|
|   | <b>2012</b>                                | <b>2011</b> |
| Cash flows from operating activities  |  |             |
| Net income  | \$ 156,649                                 | \$ 146,469  |
| Adjustments to reconcile net income to net cash provided by operating activities: |  |             |
| Gain on sale of fixed assets  |  | (2,831)     |
| Depreciation and amortization   | 27,204                                     | 27,670      |
| Amortization of intangible assets   | 30,734                                     | 25,446      |
| Amortization of debt issuance expenses  | 1,109                                      | 947         |
| Share-based compensation expense  | 11,162                                     | 9,755       |
| Deferred income taxes   | 4,621                                      | 1,623       |
| Excess tax benefit from share based compensation                                  | (3,295)                                    | (4,920)     |
| Non-cash interest expense associated with forward starting swaps                  | 5,743                                      | 2,687       |
| Changes in:   |  |             |
| Receivables   | (8,199)                                    | (18,721)    |
| Inventories   | 9,187                                      | (13,026)    |
| Trade accounts payable  | (2,797)                                    | (1,355)     |
| Accrued expenses  | 15,929                                     | 12,688      |
| Other net   | (7,549)                                    | (10,823)    |
| Net cash flows provided by operating activities                                   | 240,498                                    | 175,609     |
| Cash flows from investing activities  |  |             |
| Cash purchases of property, plant and equipment                                   | (28,108)                                   | (27,984)    |
| Proceeds from disposal of fixed assets  |  | 12,651      |
| Acquisition of businesses, net of cash acquired                                   | (69,021)                                   | (446,069)   |
| Other net   | (365)                                      | (2,262)     |
| Net cash flows used in investing activities                                       | (97,494)                                   | (463,664)   |
| Cash flows from financing activities  |  |             |
| Borrowings under revolving facilities and credit facilities for acquisitions      | 35,000                                     | 365,000     |
| Borrowings under revolving facilities   | 69,503                                     | 381,222     |
| Borrowings under credit facilities  |  | 1,883       |
| Payments under revolving facilities, credit facilities and term loan              | (130,395)                                  | (462,944)   |
| Debt issuance costs   |  | (2,433)     |
| Dividends paid  | (47,552)                                   | (40,458)    |
| Proceeds from stock option exercises  | 35,015                                     | 31,333      |
| Excess tax benefit from stock-based compensation                                  | 3,295                                      | 4,920       |
| Purchase of common stock  | (75,174)                                   |             |
| Unvested shares surrendered for tax withholding                                   | (2,326)                                    | (5,838)     |
| Other   | (1,240)                                    |             |
| Net cash flows (used in) provided by financing activities                         | (113,874)                                  | 272,685     |
| Effect of exchange rate changes on cash and cash equivalents                      | 1,114                                      | 695         |
| Net increase (decrease) in cash   | 30,244                                     | (14,675)    |

Edgar Filing: IDEX CORP /DE/ - Form 10-Q

|  |            |            |
|--|------------|------------|
| Cash and cash equivalents at beginning of year | 230,259    | 235,136    |
| Cash and cash equivalents at end of period     | \$ 260,503 | \$ 220,461 |
| <b>Supplemental cash flow information</b>      |            |            |
| Cash paid for:                                 |            |            |
| Interest                                       | \$ 22,610  | \$ 16,246  |
| Income taxes                                   | 62,053     | 46,749     |
| Significant non-cash activities:               |            |            |
| Contingent consideration for acquisition       | 8,370      | 2,707      |
| Debt acquired with acquisition of business     | 4,680      | 1,400      |

See Notes to Condensed Consolidated Financial Statements

**Table of Contents**

**IDEX CORPORATION AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

(unaudited)

**1. Basis of Presentation and Significant Accounting Policies**

The Condensed Consolidated Financial Statements of IDEX Corporation ( IDEX or the Company ) have been prepared in accordance with the instructions to Form 10-Q under the Securities Exchange Act of 1934, as amended. The statements are unaudited but include all adjustments, consisting only of recurring items, except as noted, that the Company considers necessary for a fair presentation of the information set forth herein. The results of operations for the nine months ended September 30, 2012 are not necessarily indicative of the results to be expected for the entire year.

The condensed consolidated financial statements and Management's Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2011.

***Adoption of New Accounting Standards***

In May 2011, the Financial Accounting Standards Board ( FASB ) issued Accounting Standards Update ( ASU ) 2011-04, Fair Value Measurement: Amendments to Achieve Common Fair Value Measurement and Disclosure Requirements in U.S. GAAP and IFRS ( ASU 2011-04 ), which was issued to provide a consistent definition of fair value and ensure that the fair value measurement and disclosure requirements are similar between U.S. Generally Accepted Accounting Principles ( GAAP ) and International Financial Reporting Standards ( IFRS ). ASU 2011-04 changes certain fair value measurement principles and enhances the disclosure requirements particularly for Level 3 fair value measurements. The Company adopted this guidance on January 1, 2012, and its adoption did not impact the consolidated financial position, results of operations or cash flows of the Company.

In June 2011, FASB issued ASU 2011-05 Presentation of Comprehensive Income. ASU 2011-05 allows an entity to present components of net income and other comprehensive income in one continuous statement, referred to as the statement of comprehensive income, or in two separate, but consecutive statements. The new guidance eliminates the current option to report other comprehensive income and its components in the statement of changes in equity. While ASU 2011-05 changes the presentation of comprehensive income, there are no changes to the components that are recognized in net income or other comprehensive income under current accounting guidance. In December 2011, FASB issued ASU 2011-12 Comprehensive Income (Topic 220); Deferral of the Effective Date for Amendments to the Presentation of Reclassifications of Items Out of Accumulated Other Comprehensive Income in Accounting Standards Update No. 2011-05. ASU 2011-12 deferred certain aspects of ASU 2011-05. The new guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2011. The adoption of ASU 2011-05 and the deferrals in ASU 2011-12 did not impact the consolidated financial position, results of operations or cash flows of the Company.

***New Accounting Pronouncements***

In July 2012, the FASB issued ASU 2012-02, Intangibles - Goodwill and Other (Topic 350): Testing Indefinite-Lived Intangible Assets for Impairment (ASU 2012-02), which allows an entity to first assess qualitative factors to determine whether it is necessary to perform a quantitative impairment test of an indefinite-lived intangible asset. Under ASU 2012-02, an entity would not be required to calculate the fair value of an indefinite-lived intangible asset if the entity determines, based on qualitative assessment, that it is not more likely than not impaired. The revised standard is effective for annual and interim impairment tests performed for fiscal years beginning after September 15, 2012; however, early adoption is permitted. As of September 30, 2012, the Company did not elect to early adopt ASU 2012-02; however, the Company may elect to early adopt prior to its annual test date. ASU 2012-02 is not expected to have a material impact on the consolidated financial position, results of operations or cash flows of the Company.

**Table of Contents****IDEX CORPORATION AND SUBSIDIARIES****NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)****(unaudited)****2. Restructuring**

During the second half of 2011 and into 2012, the Company recorded restructuring costs as a part of 2011 restructuring initiatives that support the implementation of key strategic efforts designed to facilitate long-term sustainable growth through cost reduction actions, primarily consisting of employee reductions and facility rationalization. The costs incurred related to these initiatives are included in Restructuring expenses in the Consolidated Statements of Operations while the restructuring accruals are included in Accrued expenses in the Consolidated Balance Sheets.

During the three and nine months ended September 30, 2012, the Company recorded \$7.1 million and \$14.6 million, respectively, of pre-tax restructuring expenses related to its 2011 restructuring initiatives for employee severance related to employee reductions across various functional areas, the termination of a defined benefit pension plan, and facility rationalization. The 2011 restructuring initiatives included severance benefits for 292 employees in 2011 and 226 employees during the first nine months of 2012.

During both the three and nine months ended September 30, 2011, the Company recorded \$2.9 million of pre-tax restructuring expenses related to the 2011 restructuring initiatives for employee severance related to employee reductions across various functional areas as well as facility rationalization.

Pre-tax restructuring expenses, by segment, for the three and nine months ended September 30, 2012, were as follows:

|                                    | Three Months<br>Ended September 30, 2012 |                 |                 | Nine Months<br>Ended September 30, 2012 |                 |                  |
|------------------------------------|--|-----------------|-----------------|---|-----------------|------------------|
|                                    | Severance                                |                 | Total           | Severance                               |                 | Total            |
|                                    | Costs                                    | Exit Costs      |                 | Costs                                   | Exit Costs      |                  |
|                                    | (in thousands)                           |                 |                 |   |                 |                  |
| Fluid & Metering Technologies      | \$ 698                                   | \$ 26           | \$ 724          | \$ 3,666                                | \$ 36           | \$ 3,702         |
| Health & Science Technologies      | 2,700                                    | 475             | 3,175           | 4,607                                   | 1,175           | 5,782            |
| Fire & Safety/Diversified Products | 450                                      | 1,618           | 2,068           | 730                                     | 2,910           | 3,640            |
| Corporate office and other         | 1,118                                    |                 | 1,118           | 1,281                                   | 199             | 1,480            |
| <b>Total restructuring costs</b>   | <b>\$ 4,966</b>                          | <b>\$ 2,119</b> | <b>\$ 7,085</b> | <b>\$ 10,284</b>                        | <b>\$ 4,320</b> | <b>\$ 14,604</b> |

Pre-tax restructuring expenses, by segment, for the three and nine months ended September 30, 2011, were as follows:

|                                    | Severance       |               | Total           |
|------------------------------------|-----------------|---------------|-----------------|
|                                    | Costs           | Exit Costs    |                 |
|                                    | (In thousands)  |               |                 |
| Fluid & Metering Technologies      | \$ 528          | \$ 51         | \$ 579          |
| Health & Science Technologies      | 407             | 21            | 428             |
| Fire & Safety/Diversified Products | 1,615           | 87            | 1,702           |
| Corporate/Other                    | 222             |               | 222             |
| <b>Total restructuring costs</b>   | <b>\$ 2,772</b> | <b>\$ 159</b> | <b>\$ 2,931</b> |



**Table of Contents****IDEX CORPORATION AND SUBSIDIARIES****NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)****(unaudited)**

Restructuring accruals of \$5.6 million and \$5.9 million at September 30, 2012 and December 31, 2011, respectively, are recorded in Accrued liabilities in the Consolidated Balance Sheets. The changes in the restructuring accrual for the nine months ended September 30, 2012 are as follows:

**(In thousands)**

|                                 |          |
|---------------------------------|----------|
| Balance at January 1, 2012      | \$ 5,875 |
| Restructuring expenses          | 14,604   |
| Payments, utilization and other | (14,851) |
| Balance at September 30, 2012   | \$ 5,628 |

**3. Acquisitions**

All of the Company's acquisitions have been accounted for under Accounting Standards Codification (ASC) 805, Business Combinations. Accordingly, the accounts of the acquired companies, after adjustments to reflect fair values assigned to assets and liabilities, have been included in the consolidated financial statements from their respective dates of acquisition.

**2012 Acquisitions**

On April 11, 2012, the Company acquired the assets of Precision Photonics Corporation (PPC). PPC specializes in optical components and coatings for applications in the fields of scientific research, aerospace, telecommunications and electronics manufacturing. Located in Boulder, Colorado, PPC has annual revenues of approximately \$7.0 million. PPC operates within the Health & Science Technologies segment as a part of the IDEX Optics and Photonics (IOP) platform. The Company acquired PPC for an aggregate purchase price of \$20.6 million in cash. The \$20.6 million cash payment was funded from operations. Goodwill and intangible assets recognized as part of this transaction were \$14.0 million and \$5.1 million, respectively. The \$14.0 million of goodwill is not deductible for tax purposes.

On April 30, 2012, the Company acquired ERC. ERC is a leader in the manufacture of gas liquid separations and detection solutions for the life science, analytical instrumentation and clinical chemistry markets. ERC's pioneering products include in-line membrane vacuum degassing solutions, refractive index detectors and ozone generation systems. ERC's original equipment degassing solutions are considered the standard for many of the world's leading instrument producers. Located in Kawaguchi, Japan, ERC has annual revenues of approximately \$27.0 million (¥2.14 billion) and operates as part of the IDEX Health & Science (IH&S) platform within the Health & Science Technologies segment. The Company acquired ERC for an aggregate purchase price of \$18.3 million (¥1.47 billion), consisting of \$13.6 million in cash and assumption of approximately \$4.7 million of debt. The cash payment was financed with borrowings under the Company's Revolving Facility. Goodwill and intangible assets recognized as part of this transaction were \$10.5 million and \$5.6 million, respectively. The \$10.5 million of goodwill is not deductible for tax purposes.

On July 20, 2012, the Company acquired Matcon Group Limited (Matcon). Matcon is a global leader in material processing solutions for high value powders used in the manufacture of pharmaceuticals, food, plastics, and fine chemicals. Matcon's innovative products include the original cone valve powder discharge system and filling, mixing and packaging systems, all of which support their customers' automation and process requirements. Matcon's products are critical to their customers' need to maintain clean, reliable and repeatable formulations of prepackaged foods and pharmaceuticals while helping them achieve lean and agile manufacturing. Located in Evesham, Worcestershire, England, Matcon has annual revenues of approximately \$34.4 million (£22.0 million) and operates within the Health & Science Technologies segment in the Material



**Table of Contents****IDEX CORPORATION AND SUBSIDIARIES****NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)****(unaudited)**

Process Technology ( MPT ) platform. The Company acquired Matcon for an aggregate purchase price of \$45.6 million (£29.1 million), consisting of \$34.8 million in cash, \$2.4 million of working capital adjustments to be paid in the fourth quarter of 2012, and contingent consideration valued at \$8.4 million as of the opening balance sheet date. The contingent consideration amount is based on 2012 and 2013 earnings before interest, income taxes, depreciation and amortization for Matcon and will be settled in the first quarter of 2013 and 2014, respectively. Based on potential outcomes, the undiscounted amount of all future payments that the Company could be required to pay under the contingent consideration arrangement is between \$0 and \$15.0 million. Approximately \$15.0 million of the purchase price cash payment was financed with borrowings under the Company's Revolving Facility. Goodwill and intangible assets recognized as part of this transaction were \$27.8 million and \$14.1 million, respectively. The \$27.8 million of goodwill is not deductible for tax purposes.

The purchase price for PPC, ERC and Matcon has been allocated to the assets acquired and liabilities assumed based on estimated fair values at the date of the acquisition. The Company is in the process of obtaining or finalizing appraisals of tangible and intangible assets and it is continuing to evaluate the initial purchase price allocations, as of the acquisition date, which will be adjusted as additional information relative to the fair values of the assets and liabilities of the businesses become known. Accordingly, management has used its best estimate in the initial purchase price allocation as of the date of these financial statements.

The allocation of the acquisition costs to the assets acquired and liabilities assumed, based on their estimated fair values, is as follows:

|  | ERC       | PPC       | Matcon    | Total     |
|--|-----------|-----------|-----------|-----------|
| <b>(In thousands)</b>                      |           |           |           |           |
| Accounts receivable                        | \$ 5,766  | \$ 877    | \$ 7,877  | \$ 14,520 |
| Inventory                                  | 4,224     | 932       | 647       | 5,803     |
| Other current assets, net of cash acquired | 607       | 251       | 1,508     | 2,366     |
| Property, plant and equipment              | 2,738     | 1,936     | 5,795     | 10,469    |
| Goodwill                                   | 10,506    | 13,986    | 27,793    | 52,285    |
| Intangible assets                          | 5,642     | 5,104     | 14,081    | 24,827    |
| Other assets                               | 67        | 13        | 130       | 210       |
| <br>                                       |           |           |           |           |
| Total assets acquired                      | 29,550    | 23,099    | 57,831    | 110,480   |
| Total liabilities assumed                  | (15,939)  | (2,509)   | (12,253)  | (30,701)  |
| <br>                                       |           |           |           |           |
| Net assets acquired                        | \$ 13,611 | \$ 20,590 | \$ 45,578 | \$ 79,779 |

Acquired intangible assets consist of trade names, non-compete agreements, customer relationships and unpatented technology. The goodwill recorded for the acquisitions reflects the strategic fit and revenue and earnings growth potential of these businesses.

The acquired intangible assets and weighted average amortization periods are as follows:

|                        | Total    | Weighted<br>Average<br>Life |
|------------------------|----------|-----------------------------|
| <b>(In thousands)</b>  |          |                             |
| Trade names            | \$ 8,973 | 15                          |
| Non-compete agreements | 470      | 3                           |
| Customer relationships | 11,343   | 6                           |



Edgar Filing: IDEX CORP /DE/ - Form 10-Q

|                                 |           |   |
|---------------------------------|-----------|---|
| Unpatented technology           | 4,041     | 8 |
| 2012 acquired intangible assets | \$ 24,827 |   |

---

**Table of Contents****IDEX CORPORATION AND SUBSIDIARIES****NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)****(unaudited)**

The Company incurred \$2.4 million of acquisition-related transaction costs in the first nine months of 2012. These costs were recorded in selling, general and administrative expense and were related to completed transactions, pending transactions and potential transactions, including certain transactions that ultimately were not completed. During the first nine months of 2012, the Company recorded \$0.9 million of fair value inventory charges associated with these acquisitions, which were recorded in cost of sales.

***2011 Acquisitions***

On January 31, 2011, the Company acquired the membership interests of AT Films. AT Films specializes in optical components and coatings for applications in the fields of scientific research, defense, aerospace, telecommunications and electronics manufacturing. AT Films' core competence is the design and manufacture of filters, splitters, reflectors and mirrors with the precise physical properties required to support their customers' most challenging and cutting-edge optical applications. Headquartered in Boulder, Colorado, AT Films has annual revenues of approximately \$9.0 million. AT Films operates within the Health & Science Technologies segment as a part of the IOP platform. The Company acquired AT Films for an aggregate purchase price of \$34.5 million, consisting of \$31.8 million in cash and contingent consideration valued at approximately \$2.7 million as of the opening balance sheet date. In February 2012, the Company paid \$1.5 million on the contingent consideration arrangement. The maximum remaining liability is \$1.5 million and is reflected in Accrued expenses in the Consolidated Balance Sheet. Goodwill and intangible assets recognized as part of this transaction were \$18.2 million and \$11.4 million, respectively. The \$18.2 million of goodwill is deductible for tax purposes.

On March 11, 2011, the Company completed the acquisition of Microfluidics. Microfluidics is a global leader in the design and manufacture of laboratory and commercial equipment used in the production of micro and nano scale materials for the pharmaceutical and chemical markets. Microfluidics is the exclusive producer of the Microfluidizer<sup>®</sup> family of high shear fluid processors for uniform particle size reduction, robust cell disruption and nanoparticle creation. Microfluidics operates within the Health & Science Technologies segment as a part of the MPT platform. The Company acquired Microfluidics for an aggregate purchase price of \$18.5 million in cash. Headquartered in Newton, Massachusetts, Microfluidics has annual revenues of approximately \$16.0 million. Goodwill and intangible assets recognized as part of this transaction were \$5.9 million and \$9.7 million, respectively. The \$5.9 million of goodwill is not deductible for tax purposes.

On June 10, 2011, the Company completed the acquisition of CVI Melles Griot ( CVI MG ). CVI MG is a global leader in the design and manufacture of precision photonic solutions used in the life sciences, research, semiconductor, security and defense markets. CVI MG's innovative products are focused on the generation, control and productive use of light for a variety of key science and industrial applications. Products include specialty lasers and light sources, electro-optical components, specialty shutters, opto-mechanical assemblies and components. In addition, CVI MG produces critical components for life science research, electronics manufacturing, military and other industrial applications including lenses, mirrors, filters and polarizers. These components are utilized in a number of important applications such as spectroscopy, cytometry (cell counting), guidance systems for target designation, remote sensing, metrology and optical lithography. CVI MG operates within the Health and Science Technologies segment as part of the IOP platform. The Company acquired CVI MG for an aggregate purchase price of \$394.7 million, consisting of \$393.3 million in cash and the assumption of approximately \$1.4 million of debt. Approximately \$365.0 million of the cash payment was financed with borrowings under the Company's Revolving Facility. Headquartered in Albuquerque, New Mexico, with manufacturing sites located on three continents, CVI MG had annual revenues of approximately \$178.0 million in 2011. Goodwill and intangible assets recognized as part of this transaction were \$208.5 million and \$115.8 million, respectively. Approximately \$117.7 million of goodwill is deductible for tax purposes.

The purchase price for CVI MG, AT Films and Microfluidics was allocated to the assets acquired and liabilities assumed based on estimated fair values at the date of the acquisition.

**Table of Contents**

**IDEX CORPORATION AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)**

**(unaudited)**

**4. Business Segments**

The Company has three reportable business segments: Fluid & Metering Technologies, Health & Science Technologies and Fire & Safety/Diversified Products.

The Fluid & Metering Technologies segment designs, produces and distributes positive displacement pumps, flow meters, injectors, and other fluid-handling pump modules and systems and provides flow monitoring and other services for the water and wastewater industries. The Health & Science Technologies segment designs, produces and distributes a wide range of precision fluidics, rotary lobe pumps, centrifugal and positive displacement pumps, roll compaction and drying systems used in beverage, food processing, pharmaceutical and cosmetics, pneumatic components and sealing solutions, including very high precision, low-flow rate pumping solutions required in analytical instrumentation, clinical diagnostics and drug discovery, high performance molded and extruded, biocompatible medical devices and implantables, air compressors used in medical, dental and industrial applications, optical components and coatings for applications in the fields of scientific research, defense, biotechnology, aerospace, telecommunications and electronics manufacturing, laboratory and commercial equipment used in the production of micro and nano scale materials, precision photonic solutions used in life sciences, research and defense markets, and precision gear and peristaltic pump technologies that meet exacting original equipment manufacturer specifications. The Fire & Safety/Diversified Products segment produces firefighting pumps and controls, rescue tools, lifting bags and other components and systems for the fire and rescue industry, engineered stainless steel banding and clamping devices used in a variety of industrial and commercial applications, and precision equipment for dispensing, metering and mixing colorants and paints used in a variety of retail and commercial businesses around the world.

**Table of Contents****IDEX CORPORATION AND SUBSIDIARIES****NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)****(unaudited)**

Information on the Company's business segments is presented below, based on the nature of products and services offered. The Company evaluates performance based on several factors, of which operating income is the primary financial measure. Intersegment sales are accounted for at fair value as if the sales were to third parties. Certain prior year amounts have been revised to include the Dispensing Equipment segment as part of the Fire & Safety/Diversified Products segment and to reflect the movement of our Trebor business unit from the Health & Science Technologies segment to the Fluid & Metering Technologies segment.

|   | Three Months           |                   | Nine Months            |                     |
|---|------------------------|-------------------|------------------------|---------------------|
|   | Ended<br>September 30, |                   | Ended<br>September 30, |                     |
|   | 2012                   | 2011              | 2012                   | 2011                |
|   | (In thousands)         |                   |                        |                     |
| <i>Net sales:</i>                                       |                        |                   |                        |                     |
| Fluid & Metering Technologies:                          |                        |                   |                        |                     |
| External customers                                      | \$ 197,620             | \$ 205,674        | \$ 620,451             | \$ 614,008          |
| Intersegment sales                                      | 380                    | 123               | 982                    | 359                 |
| <b>Total group sales</b>                                | <b>198,000</b>         | <b>205,797</b>    | <b>621,433</b>         | <b>614,367</b>      |
| Health & Science Technologies:                          |                        |                   |                        |                     |
| External customers                                      | 174,351                | 172,648           | 516,314                | 441,635             |
| Intersegment sales                                      | 1,874                  | 263               | 4,260                  | 984                 |
| <b>Total group sales</b>                                | <b>176,225</b>         | <b>172,911</b>    | <b>520,574</b>         | <b>442,619</b>      |
| Fire & Safety/Diversified Products:                     |                        |                   |                        |                     |
| External customers                                      | 107,888                | 98,559            | 326,655                | 302,125             |
| Intersegment sales                                      | 311                    | 176               | 1,518                  | 689                 |
| <b>Total group sales</b>                                | <b>108,199</b>         | <b>98,735</b>     | <b>328,173</b>         | <b>302,814</b>      |
| Intersegment elimination                                | (2,565)                | (562)             | (6,760)                | (2,032)             |
| <b>Total net sales</b>                                  | <b>\$ 479,859</b>      | <b>\$ 476,881</b> | <b>\$ 1,463,420</b>    | <b>\$ 1,357,768</b> |
| <i>Operating income and income before income taxes:</i> |                        |                   |                        |                     |
| Fluid & Metering Technologies                           | \$ 41,649              | \$ 40,883         | \$ 132,477             | \$ 124,221          |
| Health & Science Technologies                           | 27,305                 | 19,287            | 84,711                 | 75,653              |
| Fire & Safety/Diversified Products                      | 24,738                 | 19,263            | 74,524                 | 67,270              |
| Corporate office and other                              | (13,104)               | (8,128)           | (37,905)               | (38,489)            |
| <b>Total operating income</b>                           | <b>80,588</b>          | <b>71,305</b>     | <b>253,807</b>         | <b>228,655</b>      |
| Interest expense  | 10,536                 | 7,763             | 31,734                 | 20,937              |
| Other income (expense)-net                              | 132                    | (441)             | 19                     | (1,001)             |

Edgar Filing: IDEX CORP /DE/ - Form 10-Q

Income before income taxes \$ 70,184 \$ 63,101 \$ 222,092 \$ 206,717

|   | September 30,<br>2012 | December 31,<br>2011 |
|---|-----------------------|----------------------|
|   | (In thousands)        |                      |
| <i>Assets:</i>                            |                       |                      |
| Fluid & Metering Technologies             | \$ 1,045,783          | \$ 1,072,023         |
| Health & Science Technologies             | 1,295,881             | 1,178,653            |
| Fire & Safety/Diversified Products        | 469,785               | 442,400              |
| Corporate office and other <sup>(1)</sup> | 145,986               | 143,031              |
| <br>Total assets                          | <br>\$ 2,957,435      | <br>\$ 2,836,107     |

(1) Includes intersegment eliminations.

**Table of Contents****IDEX CORPORATION AND SUBSIDIARIES****NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)****(unaudited)****5. Earnings Per Common Share**

Earnings per common share ( EPS ) are computed by dividing net income by the weighted average number of shares of common stock (basic) plus common stock equivalents outstanding (diluted) during the period. Common stock equivalents consist of stock options, which have been included in the calculation of weighted average shares outstanding using the treasury stock method, unvested shares, and shares issuable in connection with certain deferred compensation agreements ( DCUs ).

ASC 260 Earnings Per Share , provides that all outstanding unvested share-based payment awards that contain rights to nonforfeitable dividends participate in undistributed earnings with common shareholders. If awards are considered participating securities, the Company is required to apply the two-class method of computing basic and diluted earnings per share. The Company has determined that its outstanding unvested shares are participating securities. Accordingly, earnings per common share are computed using the two-class method prescribed by ASC 260. Net income attributable to common shareholders was reduced by \$0.2 million and \$0.3 million for the three months ended September 30, 2012 and 2011, respectively. Net income attributable to common shareholders was reduced by \$0.6 million and \$1.0 million for the nine months ended September 30, 2012 and 2011, respectively.

Basic weighted average shares reconciles to diluted weighted average shares as follows:

|   | <b>Three Months</b>        |             | <b>Nine Months</b>         |             |
|---|----------------------------|-------------|----------------------------|-------------|
|   | <b>Ended September 30,</b> |             | <b>Ended September 30,</b> |             |
|   | <b>2012</b>                | <b>2011</b> | <b>2012</b>                | <b>2011</b> |
|   | <b>(In thousands)</b>      |             |                            |             |
| Basic weighted average common shares outstanding            | 82,482                     | 82,402      | 82,820                     | 81,994      |
| Dilutive effect of stock options, unvested shares, and DCUs | 888                        | 1,184       | 965                        | 1,539       |
| Diluted weighted average common shares outstanding          | 83,370                     | 83,586      | 83,785                     | 83,533      |

Options to purchase approximately 1.3 million and 0.2 million shares of common stock for the three months ended September 30, 2012 and 2011, respectively, and options to purchase approximately 1.3 million and 0.9 million shares of common stock for the nine months ended September 30, 2012 and 2011, respectively, were not included in the computation of diluted EPS because the exercise price was greater than the average market price of the Company's common stock and, therefore, the effect of their inclusion would be antidilutive.

**6. Inventories**

The components of inventories as of September 30, 2012 and December 31, 2011 were:

|                                   | <b>September 30,</b>  | <b>December 31,</b> |
|-----------------------------------|-----------------------|---------------------|
|                                   | <b>2012</b>           | <b>2011</b>         |
|                                   | <b>(In thousands)</b> |                     |
| Raw materials and component parts | \$ 147,177            | \$ 155,577          |
| Work-in-process                   | 38,467                | 40,506              |
| Finished goods                    | 63,920                | 58,175              |

Edgar Filing: IDEX CORP /DE/ - Form 10-Q

|       |            |            |
|-------|------------|------------|
| Total | \$ 249,564 | \$ 254,258 |
|-------|------------|------------|

Inventories are stated at the lower of cost or market. Cost, which includes material, labor, and factory overhead, is determined on a FIFO basis.

**Table of Contents****IDEX CORPORATION AND SUBSIDIARIES****NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)****(unaudited)****7. Goodwill and Intangible Assets**

The changes in the carrying amount of goodwill for the nine months ended September 30, 2012, by reportable business segment, were as follows:

| (In thousands)                              | Fluid &<br>Metering<br>Technologies | Health &<br>Science<br>Technologies | Fire &<br>Safety/<br>Diversified<br>Products | Total        |
|---|-------------------------------------|-------------------------------------|--|--------------|
| Balance at December 31, 2011 <sup>(1)</sup> | \$ 541,640                          | \$ 648,906                          | \$ 240,820                                   | \$ 1,431,366 |
| Acquisition adjustments                     |                                     | 1,424                               |  | 1,424        |
| Foreign currency translation                | 981                                 | 4,548                               | 217  | 5,746        |
| Acquisition                                 |                                     | 52,285                              |  | 52,285       |
| Balance at September 30, 2012               | \$ 542,621                          | \$ 707,163                          | \$ 241,037                                   | \$ 1,490,821 |

(1) Revised to reflect the movement of the Dispensing Equipment segment to the Fire & Safety/Diversified Products segment and the transfer of \$20.6 million of goodwill related to the movement of our Trebor business unit within the Health & Science Technologies segment to the Fluid & Metering Technologies segment.

ASC 350 Goodwill and Other Intangible Assets requires that goodwill be tested for impairment at the reporting unit level on an annual basis and between annual tests if an event occurs or circumstances change that would more likely than not reduce the fair value of the reporting unit below its carrying value. Annually on October 31, goodwill and other acquired intangible assets with indefinite lives are tested for impairment. The Company concluded that the fair value of each of the reporting units was in excess of the carrying value as of October 31, 2011. The Company did not consider there to be any triggering event that would require an interim impairment assessment, therefore none of the goodwill or other acquired intangible assets with indefinite lives were tested for impairment during the three months ended September 30, 2012. However, if market conditions deteriorate, the Water reporting unit, the Optics and Photonics reporting unit and the CVI and Melles Griot trade names could potentially be at risk for an impairment charge. As of September 30, 2012, the total goodwill balance of the Water and the Optics and Photonics reporting units was \$219.7 million and \$279.3 million, respectively.

The following table provides the gross carrying value and accumulated amortization for each major class of intangible asset at September 30, 2012 and December 31, 2011:

|                              | At September 30, 2012       |   |          | Weighted<br>Average<br>Life | At December 31, 2011        |   |          |
|------------------------------|-----------------------------|---|----------|-----------------------------|-----------------------------|---|----------|
|                              | Gross<br>Carrying<br>Amount | Accumulated<br>Amortization<br>(In thousands) | Net      |                             | Gross<br>Carrying<br>Amount | Accumulated<br>Amortization<br>(In thousands) | Net      |
| Amortized intangible assets: |                             |   |          |                             |                             |   |          |
| Patents                      | \$ 10,478                   | \$ (4,002)                                    | \$ 6,476 | 11                          | \$ 11,506                   | \$ (4,315)                                    | \$ 7,191 |
| Trade names                  | 82,585                      | (21,839)                                      | 60,746   | 16                          | 72,823                      | (18,205)                                      | 54,618   |



Edgar Filing: IDEX CORP /DE/ - Form 10-Q

|                                   |            |              |            |    |            |              |            |
|-----------------------------------|------------|--------------|------------|----|------------|--------------|------------|
| Customer relationships            | 233,551    | (88,701)     | 144,850    | 10 | 221,076    | (69,280)     | 151,796    |
| Non-compete agreements            | 3,560      | (2,734)      | 826        | 3  | 4,801      | (4,053)      | 748        |
| Unpatented technology             | 75,492     | (22,248)     | 53,244     | 11 | 70,741     | (15,617)     | 55,124     |
| Other                             | 6,871      | (3,461)      | 3,410      | 10 | 6,793      | (3,156)      | 3,637      |
| Total amortized intangible assets | 412,537    | (142,985)    | 269,552    |    | 387,740    | (114,626)    | 273,114    |
| Unamortized intangible assets:    |            |              |            |    |            |              |            |
| Banjo trade name                  | 62,100     |              | 62,100     |    | 62,100     |              | 62,100     |
| CVI and Melles Griot trade names  | 47,008     |              | 47,008     |    | 47,008     |              | 47,008     |
| Total intangible assets           | \$ 521,645 | \$ (142,985) | \$ 378,660 |    | \$ 496,848 | \$ (114,626) | \$ 382,222 |

**Table of Contents****IDEX CORPORATION AND SUBSIDIARIES****NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)****(unaudited)**

The unamortized trade names are indefinite lived intangible assets which are tested for impairment on an annual basis or more frequently if events or changes in circumstances indicate that the asset might be impaired.

**8. Accrued Expenses**

The components of accrued expenses as of September 30, 2012 and December 31, 2011 were:

|  | September 30,<br>2012 | December 31,<br>2011 |
|--|-----------------------|----------------------|
|  | (In thousands)        |                      |
| Payroll and related items                | \$ 56,395             | \$ 51,728            |
| Management incentive compensation        | 12,531                | 17,402               |
| Income taxes payable                     | 9,697                 | 8,456                |
| Deferred income taxes                    | 306                   | 167                  |
| Insurance                                | 6,861                 | 6,495                |
| Warranty                                 | 4,865                 | 4,417                |
| Deferred revenue                         | 16,147                | 7,954                |
| Restructuring                            | 5,628                 | 5,875                |
| Liability for uncertain tax positions    | 1,696                 | 1,061                |
| Accrued interest                         | 9,439                 | 1,424                |
| Contingent consideration for acquisition | 4,355                 | 1,500                |
| Other                                    | 26,637                | 24,217               |
| <b>Total accrued expenses</b>            | <b>\$ 154,557</b>     | <b>\$ 130,696</b>    |

**9. Other Noncurrent Liabilities**

The components of noncurrent liabilities as of September 30, 2012 and December 31, 2011 were:

|  | September 30,<br>2012 | December 31,<br>2011 |
|--|-----------------------|----------------------|
|  | (In thousands)        |                      |
| Pension and retiree medical obligations    | \$ 85,698             | \$ 91,542            |
| Liability for uncertain tax positions      | 3,574                 | 5,262                |
| Deferred revenue                           | 5,657                 | 3,198                |
| Contingent consideration for acquisition . | 5,515                 |                      |
| Other                                      | 13,373                | 15,844               |
| <b>Total other noncurrent liabilities</b>  | <b>\$ 113,817</b>     | <b>\$ 115,846</b>    |

**Table of Contents****IDEX CORPORATION AND SUBSIDIARIES****NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)****(unaudited)****10. Borrowings**

Borrowings at September 30, 2012 and December 31, 2011 consisted of the following:

|  | September 30,<br>2012 | December 31,<br>2011 |
|--|-----------------------|----------------------|
|  | (In thousands)        |                      |
| Revolving Facility                     | \$ 27,000             | \$ 50,798            |
| 4.2% Senior Notes, due December 2021   | 349,179               | 349,125              |
| 4.5% Senior Notes, due December 2020   | 298,655               | 298,555              |
| 2.58% Senior Euro Notes, due June 2015 | 104,328               | 104,655              |
| Other borrowings                       | 8,758                 | 5,677                |
| <b>Total borrowings</b>                | <b>787,920</b>        | <b>808,810</b>       |
| <b>Less current portion</b>            | <b>5,152</b>          | <b>2,444</b>         |
| <b>Total long-term borrowings</b>      | <b>\$ 782,768</b>     | <b>\$ 806,366</b>    |

On June 27, 2011, the Company and certain of its subsidiaries entered into a credit agreement (the *Credit Agreement*), as borrowers (the *Borrowers*), with Bank of America, N.A., as administrative agent, swing line lender and an issuer of letters of credit, and other lenders party thereto which provided for a new revolving credit facility (the *Revolving Facility*). The *Revolving Facility* replaced the Company's previous \$600.0 million credit facility, which expired in December 2011.

The *Revolving Facility* is in an aggregate principal amount of \$700.0 million with a maturity date of June 27, 2016. The maturity date may be extended under certain conditions for an additional one-year term prior to the second anniversary of the initial closing date of June 27, 2011. Up to \$75.0 million of the *Revolving Facility* is available for the issuance of letters of credit. Additionally, up to \$25.0 million of the *Revolving Facility* is available to the Company for swing line loans, available on a same-day basis.

Proceeds of the *Revolving Facility* are available for use by the *Borrowers* for working capital and other general corporate purposes, including refinancing existing debt of the Company and its subsidiaries. The Company may request increases in the lending commitments under the *Credit Agreement*, but the aggregate lending commitments may not exceed \$950.0 million. The Company has the right, subject to certain conditions set forth in the *Credit Agreement*, to designate certain foreign subsidiaries of the Company as borrowers under the *Credit Agreement*. In connection with any such designation, the Company is required to guarantee the obligations of any such subsidiaries under the *Credit Agreement*. Under the *Credit Agreement*, Fluid Management Europe B.V., ( *FME* ) and IDEX UK Ltd. ( *IDEX UK* ) were approved by the lenders as designated borrowers. At September 30, 2012, *FME* and *IDEX UK* had no borrowings under the *Revolving Facility*.

Borrowings under the *Revolving Facility* bear interest, at either an alternate base rate or an adjusted LIBOR rate plus, an applicable margin. Such applicable margin is based on the Company's senior, unsecured, long-term debt rating and can range from .875% to 1.70%. Based on the Company's credit rating at September 30, 2012, the applicable margin was 1.05%. Interest is payable (a) in the case of base rate loans, quarterly, and (b) in the case of LIBOR rate loans, on the maturity date of the borrowing, or quarterly from the effective date for borrowings exceeding three months. An annual *Revolving Facility* fee, also based on the Company's credit rating, is currently 20 basis points and is payable quarterly.

The *Credit Agreement* contains affirmative and negative covenants that the Company believes are usual and customary for senior unsecured credit agreements, including a financial covenant requiring the maintenance of a 3.25 to 1.0 or lower leverage ratio, which is the ratio of the Company's consolidated total debt to its consolidated EBITDA, each as defined in the *Credit Agreement*.



**Table of Contents**

**IDEX CORPORATION AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)**

**(unaudited)**

The Credit Agreement also contains customary events of default (subject to grace periods, as appropriate) including among others: nonpayment of principal, interest or fees; breach of the representations or warranties in any material respect; breach of the financial, affirmative or negative covenants; payment default on, or acceleration of, other material indebtedness; bankruptcy or insolvency; material judgments entered against the Company or any of its subsidiaries; certain specified events under the Employee Retirement Income Security Act of 1974, as amended; certain changes in control of the Company; and the invalidity or unenforceability of the Credit Agreement or other documents associated with the Credit Agreement.

At September 30, 2012, there were \$27.0 million outstanding borrowings under the Revolving Facility and \$7.1 million of outstanding letters of credit. The net available borrowing capacity under the Revolving Facility at September 30, 2012, was approximately \$665.9 million.

On June 9, 2010, the Company completed a private placement of \$81.0 million (\$96.8 million) aggregate principal amount of 2.58% Series 2010 Senior Euro Notes due June 9, 2015 ( 2.58% Senior Euro Notes ) pursuant to a Master Note Purchase Agreement, dated June 9, 2010 (the Purchase Agreement ). The Purchase Agreement provides for the issuance of additional series of notes in the future, provided that the aggregate principal amount outstanding under the agreement at any time does not exceed \$750.0 million. The 2.58% Senior Euro Notes bear interest at a rate of 2.58% per annum, which is payable semi-annually in arrears on each June 9<sup>th</sup> and December 9<sup>th</sup> and will mature on June 9, 2015. The 2.58% Senior Euro Notes are unsecured obligations of the Company and rank pari passu in right of payment with all of the Company's other senior debt. The Company may at any time prepay all or any portion of the 2.58% Senior Euro Notes; provided that any such portion is greater than 5% of the aggregate principal amount of Notes then outstanding under the Purchase Agreement. In the event of a prepayment, the Company would be required to pay an amount equal to par plus accrued interest plus a make-whole premium. The Purchase Agreement contains certain covenants that restrict the Company's ability to, among other things, transfer or sell assets, create liens and engage in certain mergers or consolidations. In addition, the Company must comply with a leverage ratio and interest coverage ratio as set forth in the Purchase Agreement. The Purchase Agreement provides for customary events of default. In the case of an event of default arising from specified events of bankruptcy or insolvency, all outstanding 2.58% Senior Euro Notes will become due and payable immediately without further action or notice. In the case of payment events of defaults, any holder of the 2.58% Senior Euro Notes affected thereby may declare all the 2.58% Senior Euro Notes held by it due and payable immediately. In the case of any other event of default, a majority of the holders of the 2.58% Senior Euro Notes may declare all the 2.58% Senior Euro Notes to be due and payable immediately.

On December 6, 2010, the Company completed a public offering of \$300.0 million 4.5% senior notes due December 15, 2020 ( 4.5% Senior Notes ). The net proceeds from the offering of \$295.7 million, after deducting the \$1.6 million issuance discount, the \$1.9 million underwriting commission and \$0.8 million offering expenses, were used to repay \$250.0 million of outstanding bank indebtedness, with the balance used for general corporate purposes. The 4.5% Senior Notes bear interest at a rate of 4.5% per annum, which is payable semi-annually in arrears on each June 15<sup>th</sup> and December 15<sup>th</sup>. The Company may redeem all or a portion of the 4.5% Senior Notes at any time prior to maturity at the redemption prices set forth in the Note Indenture governing the 4.5% Senior Notes. The Company may issue additional debt from time to time pursuant to the Indenture. The Indenture and 4.5% Senior Notes contain covenants that limit the Company's ability to, among other things, incur certain liens securing indebtedness, engage in certain sale-leaseback transactions, and enter into certain consolidations, mergers, conveyances, transfers or leases of all or substantially all the Company's assets. The terms of the 4.5% Senior Notes also require the Company to make an offer to repurchase the 4.5% Senior Notes upon a change of control triggering event (as defined in the Indenture) at a price equal to 101% of their principal amount plus accrued and unpaid interest, if any.

**Table of Contents**

**IDEX CORPORATION AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)**

**(unaudited)**

On December 9, 2011, the Company completed a public offering of \$350.0 million 4.2% senior notes due December 15, 2021 ( 4.2% Senior Notes ). The net proceeds from the offering of \$346.2 million, after deducting the \$0.9 million issuance discount, the \$2.3 million underwriting commission and \$0.6 million offering expenses, were used to repay \$306.0 million of outstanding bank indebtedness, with the balance used for general corporate purposes. The 4.2% Senior Notes bear interest at a rate of 4.2% per annum, which is payable semi-annually in arrears on each June 15<sup>th</sup> and December 15<sup>th</sup>. The Company may redeem all or a portion of the 4.2% Senior Notes at any time prior to maturity at the redemption prices set forth in the Note Indenture governing the 4.2% Senior Notes. The Company may issue additional debt from time to time pursuant to the Indenture. The Indenture and 4.2% Senior Notes contain covenants that limit the Company's ability to, among other things, incur certain liens securing indebtedness, engage in certain sale-leaseback transactions, and enter into certain consolidations, mergers, conveyances, transfers or leases of all or substantially all the Company's assets. The terms of the 4.2% Senior Notes also require the Company to make an offer to repurchase the 4.2% Senior Notes upon a change of control triggering event (as defined in the Indenture) at a price equal to 101% of their principal amount plus accrued and unpaid interest, if any.

Other borrowings of \$8.8 million at September 30, 2012 were comprised of capital leases, debt at international locations maintained for working capital purposes and international debt as a result of acquisitions. Interest is payable on the outstanding debt balances at the international locations at rates ranging from 0.4% to 3.7% per annum.

There are two key financial covenants that the Company is required to maintain in connection with the Revolving Facility and 2.58% Senior Euro Notes. The most restrictive financial covenants under these debt instruments require a minimum interest coverage ratio of 3.0 to 1 and a maximum leverage ratio of 3.25 to 1. At September 30, 2012, the Company was in compliance with both of these financial covenants. There are no financial covenants relating to the 4.5% Senior Notes or 4.2% Senior Notes.

**11. Derivative Instruments**

The Company enters into cash flow hedges to reduce the exposure to variability in certain expected future cash flows. The type of cash flow hedges the Company enters into includes foreign currency contracts and interest rate exchange agreements that effectively convert a portion of floating-rate debt to fixed-rate debt and are designed to reduce the impact of interest rate changes on future interest expense.

The effective portion of gains or losses on interest rate exchange agreements is reported in accumulated other comprehensive income (loss) in shareholders' equity and reclassified into net income in the same period or periods in which the hedged transaction affects net income. The remaining gain or loss in excess of the cumulative change in the present value of future cash flows or the hedged item, if any, is recognized into net income during the period of change.

Fair values relating to derivative financial instruments reflect the estimated amounts that the Company would receive or pay to sell or buy the contracts based on quoted market prices of comparable contracts at each balance sheet date.

On April 15, 2010, the Company entered into a forward starting interest rate contract with a notional amount of \$300.0 million with a settlement date in December 2010. This contract was entered into in anticipation of the issuance of the 4.5% Senior Notes and was designed to lock in the market interest rate as of April 15, 2010. In December 2010, the Company settled and paid this interest rate contract for \$31.0 million. The \$31.0 million is being amortized into interest expense over the 10 year term of the 4.5% Senior Notes, which results in an effective interest rate of 5.8%.

**Table of Contents****IDEX CORPORATION AND SUBSIDIARIES****NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)****(unaudited)**

On July 12, 2011, the Company entered into a forward starting interest rate contract with a notional amount of \$350.0 million and a settlement date of September 30, 2011. This contract was entered into in anticipation of the issuance of the 4.2% Senior Notes and was designed to lock in the market interest rate as of July 12, 2011. On September 29, 2011, the Company settled this interest rate contract for \$34.7 million with a payment made on October 3, 2011. Simultaneously, the Company entered into a separate interest rate contract with a notional amount of \$350.0 million and a settlement date of February 28, 2012. The contract was entered into in anticipation of the expected issuance of the 4.2% Senior Notes and was designed to maintain the market rate as of July 12, 2011. In December 2011, the Company settled and paid the September interest rate contract for \$4.0 million, resulting in a total settlement of \$38.7 million. Of the \$38.7 million, \$0.8 million was recognized as other expense in 2011 and the balance of \$37.9 million is being amortized into interest expense over the 10 year term of the 4.2% Senior Notes, which results in an effective interest rate of 5.3%.

As of September 30, 2012, the Company did not have any interest rate contracts outstanding.

The following table summarizes the gain (loss) recognized and the amounts and location of income (expense) and gain (loss) reclassified into income for interest rate contracts and foreign currency contracts for September 30, 2012 and 2011:

|                          | Gain (Loss)<br>Recognized in Other<br>Comprehensive<br>Income |             | (Expense)<br>and Gain<br>Reclassified into<br>Income |            | Income<br>Statement Caption |
|--------------------------|---|-------------|--|------------|-----------------------------|
|                          | Three Months Ended September 30,                              |             |  |            |                             |
|                          | 2012  | 2011        | 2012   | 2011       |                             |
|                          | (In thousands)  |             |  |            |                             |
| Interest rate agreements | \$  | \$ (36,295) | \$ (1,898)   | \$ (1,515) | Interest expense            |

|                            | Gain (Loss)<br>Recognized in Other<br>Comprehensive<br>Income |             | (Expense)<br>and Gain<br>Reclassified into<br>Income |            | Income<br>Statement Caption |
|----------------------------|---|-------------|--|------------|-----------------------------|
|                            | Nine Months Ended September 30,                               |             |  |            |                             |
|                            | 2012  | 2011        | 2012   | 2011       |                             |
|                            | (In thousands)  |             |  |            |                             |
| Interest rate agreements   | \$  | \$ (36,407) | \$ (5,743)   | \$ (4,593) | Interest expense            |
| Foreign exchange contracts |   | (55)        |  | 227        | Sales                       |

Approximately \$7.5 million of the pre-tax amount included in accumulated other comprehensive income (loss) in shareholders' equity at September 30, 2012 will be recognized to net income over the next 12 months as the underlying hedged transactions are realized.

**12. Fair Value Measurements**

ASC 820 Fair Value Measurements and Disclosures defines fair value, provides guidance for measuring fair value and requires certain disclosures. This standard discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). The standard utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels:

Edgar Filing: IDEX CORP /DE/ - Form 10-Q

Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.



**Table of Contents****IDEX CORPORATION AND SUBSIDIARIES****NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)****(unaudited)**

Level 2: Inputs, other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.

Level 3: Unobservable inputs that reflect the reporting entity's own assumptions.

The following table summarizes the basis used to measure the Company's financial assets and (liabilities) at fair value on a recurring basis in the balance sheet at September 30, 2012 and December 31, 2011:

|                               | <b>Basis of Fair Value Measurements</b> |                       |                |                |
|-------------------------------|---|-----------------------|----------------|----------------|
|                               | <b>Balance</b>                          | <b>Level 1</b>        | <b>Level 2</b> | <b>Level 3</b> |
|                               | <b>at</b>                               |                       |                |                |
|                               | <b>September 30, 2012</b>               |                       |                |                |
|                               |   | <b>(In thousands)</b> |                |                |
| Money market investment       | \$ 8,681                                | \$ 8,681              | \$             | \$             |
| Available for sale securities | 2,908                                   | 2,908                 |                |                |
| Contingent consideration      | (9,870)                                 |                       |                | (9,870)        |

|                               | <b>Basis of Fair Value Measurements</b> |                       |                |                |
|-------------------------------|---|-----------------------|----------------|----------------|
|                               | <b>Balance</b>                          | <b>Level 1</b>        | <b>Level 2</b> | <b>Level 3</b> |
|                               | <b>at</b>                               |                       |                |                |
|                               | <b>December 31, 2011</b>                |                       |                |                |
|                               |   | <b>(In thousands)</b> |                |                |
| Money market investment       | \$ 11,899                               | \$ 11,899             | \$             | \$             |
| Available for sale securities | 2,785                                   | 2,785                 |                |                |
| Contingent consideration      | (3,000)                                 |                       |                | (3,000)        |

There were no transfers of assets or liabilities between Level 1 and Level 2 during the first nine months of 2012 or 2011.

In determining the fair value of the contingent consideration potentially due with the acquisitions of AT Films and Matcon, the Company used probability weighted estimates adjusted for the time value of money. In February 2012, the Company paid \$1.5 million as contingent consideration for AT Films. The maximum remaining liability on the AT Films contingent consideration is \$1.5 million and is reflected in Accrued expenses in the Consolidated Balance Sheet. The Matcon contingent consideration liability is valued at \$8.4 million, of which \$2.9 million is included in Accrued expenses and \$5.5 million is recorded in Noncurrent liabilities in the Consolidated Balance Sheet.

The carrying value of our cash and cash equivalents, accounts receivable, accounts payable and accrued expenses approximates their fair values because of the short term nature of these instruments. At September 30, 2012, the fair value of our Revolving Facility, 2.58% Senior Euro Notes, 4.5% Senior Notes and 4.2% Senior Notes, based on quoted market prices and current market rates for debt with similar credit risk and maturity, was approximately \$819.3 million compared to the carrying value of \$779.2 million. This fair value measurement is classified as Level 2 within the fair value hierarchy since it is determined based upon significant inputs observable in the market, including interest rates on recent financing transactions to entities with a credit rating similar to ours.

**13. Common and Preferred Stock**

On December 6, 2011, the Company announced that its Board of Directors increased the authorized level for repurchases of its common stock by approximately \$50.0 million. The increased authorization is in addition to the approximately \$75.0 million that remains available from the

prior authorization approved by the Board of

**Table of Contents****IDEX CORPORATION AND SUBSIDIARIES****NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)****(unaudited)**

Directors on April 21, 2008, resulting in a total authorized repurchase amount of \$125.0 million. During the nine months ended September 30, 2012, the Company has purchased a total of 1.9 million shares at a cost of \$75.2 million.

At September 30, 2012 and December 31, 2011, the Company had 150 million shares of authorized common stock, with a par value of \$.01 per share, and 5 million shares of authorized preferred stock, with a par value of \$.01 per share. No preferred stock was issued at September 30, 2012 and December 31, 2011.

**14. Share-Based Compensation**

During the nine months ended September 30, 2012, the Company granted approximately 0.8 million stock options and 0.2 million unvested shares, respectively. During the nine months ended September 30, 2011, the Company granted approximately 0.8 million stock options and 0.3 million unvested shares, respectively.

Weighted average option fair values and assumptions for the periods specified are disclosed in the following table:

|  | <b>Three Months Ended<br/>September 30,</b> |               |
|--|---|---------------|
|  | <b>2012</b>                                 | <b>2011</b>   |
| Weighted average fair value of option grants | \$ 9.55                                     | \$ 11.66      |
| Dividend yield                               | 2.07%                                       | 1.63%         |
| Volatility                                   | 31.96%                                      | 31.84%        |
| Risk-free forward interest rate              | 0.18% - 3.34%                               | 0.18% - 5.15% |
| Expected life (in years)                     | 5.89  | 6.08          |

|  | <b>Nine Months Ended<br/>September 30,</b> |               |
|--|--|---------------|
|  | <b>2012</b>                                | <b>2011</b>   |
| Weighted average fair value of option grants | \$11.40                                    | \$12.31       |
| Dividend yield                               | 1.59%                                      | 1.45%         |
| Volatility                                   | 32.01%                                     | 32.72%        |
| Risk-free forward interest rate              | 0.17% - 3.97%                              | 0.28% - 5.62% |
| Expected life (in years)                     | 5.97                                       | 6.14          |

The assumptions are as follows:

The Company estimated volatility using its historical share price performance over the contractual term of the option.

The Company uses historical data to estimate the expected life of the option. The expected life assumption for the three and nine months ended September 30, 2012 and 2011 is an output of the Binomial lattice option-pricing model, which incorporates vesting provisions, rate of voluntary exercise and rate of post-vesting termination over the contractual life of the option to define expected employee behavior.

## Edgar Filing: IDEX CORP /DE/ - Form 10-Q

The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods within the contractual life of the option. For the three and nine months ended September 30, 2012 and 2011, we present the range of risk-free one-year forward rates, derived from the U.S. treasury yield curve, utilized in the Binomial lattice option-pricing model.

**Table of Contents****IDEX CORPORATION AND SUBSIDIARIES****NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)****(unaudited)**

The expected dividend yield is based on the Company's current dividend yield as the best estimate of projected dividend yield for periods within the contractual life of the option.

The Company's policy is to recognize compensation cost on a straight-line basis over the requisite service period for the entire award. Additionally, the Company's general policy is to issue authorized and unissued shares of common stock to satisfy stock option exercises or grants of unvested shares.

Total compensation cost for the stock options is as follows:

|  | Three Months<br>Ended<br>September 30, |               | Nine Months<br>Ended<br>September 30, |                 |
|--|--|---------------|---------------------------------------|-----------------|
|  | 2012                                   | 2011          | 2012                                  | 2011            |
|  | (In thousands)                         |               |                                       |                 |
| Cost of goods sold                           | \$ 111                                 | \$ 202        | \$ 593                                | \$ 645          |
| Selling, general and administrative expenses | 1,233                                  | 1,157         | 4,661                                 | 5,140           |
| <b>Total expense before income taxes</b>     | <b>1,344</b>                           | <b>1,359</b>  | <b>5,254</b>                          | <b>5,785</b>    |
| Income tax benefit                           | (442)                                  | (390)         | (1,642)                               | (1,842)         |
| <b>Total expense after income taxes</b>      | <b>\$ 902</b>                          | <b>\$ 969</b> | <b>\$ 3,612</b>                       | <b>\$ 3,943</b> |

Total compensation cost for the unvested shares is as follows:

|  | Three Months<br>Ended<br>September 30, |                     | Nine Months<br>Ended<br>September 30, |                     |
|--|--|---------------------|---------------------------------------|---------------------|
|  | 2012                                   | 2011 <sup>(1)</sup> | 2012                                  | 2011 <sup>(1)</sup> |
|  | (In thousands)                         |                     |                                       |                     |
| Cost of goods sold                           | \$ 199                                 | \$ 197              | \$ 802                                | \$ 495              |
| Selling, general and administrative expenses | 1,443                                  | (1,883)             | 5,106                                 | 3,475               |
| <b>Total expense before income taxes</b>     | <b>1,642</b>                           | <b>(1,686)</b>      | <b>5,908</b>                          | <b>3,970</b>        |
| Income tax benefit                           | (412)                                  | (451)               | (1,552)                               | (1,537)             |
| <b>Total expense after income taxes</b>      | <b>\$ 1,230</b>                        | <b>\$ (2,137)</b>   | <b>\$ 4,356</b>                       | <b>\$ 2,433</b>     |

(1) Reflects the forfeiture of unvested shares related to the Company's transition to a new CEO in August 2011.

Classification of stock compensation cost within the Consolidated Statements of Operations is consistent with classification of cash compensation for the same employees and \$0.2 million of compensation cost was capitalized as part of inventory at both September 30, 2012 and December 31, 2011.

## Edgar Filing: IDEX CORP /DE/ - Form 10-Q

As of September 30, 2012, there was \$10.1 million of total unrecognized compensation cost related to stock options that is expected to be recognized over a weighted-average period of 1.5 years, and \$10.9 million of total unrecognized compensation cost related to unvested shares that is expected to be recognized over a weighted-average period of 1.1 years.

**Table of Contents****IDEX CORPORATION AND SUBSIDIARIES****NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)****(unaudited)****15. Retirement Benefits**

The Company sponsors several qualified and nonqualified defined benefit and defined contribution pension plans and other postretirement plans for its employees. The following tables provide the components of net periodic benefit cost for its major defined benefit plans and its other postretirement plans.

|                                  | <b>Pension Benefits</b>                      |                 |                 |                 |
|----------------------------------|--|-----------------|-----------------|-----------------|
|                                  | <b>Three Months Ended September 30, 2012</b> |                 | <b>2011</b>     |                 |
|                                  | <b>U.S.</b>                                  | <b>Non-U.S.</b> | <b>U.S.</b>     | <b>Non-U.S.</b> |
|                                  | <b>(In thousands)</b>                        |                 |                 |                 |
| Service cost                     | \$ 239                                       | \$ 328          | \$ 399          | \$ 207          |
| Interest cost                    | 876  | 527             | 1,116           | 587             |
| Expected return on plan assets   | (964)  | (256)           | (1,171)         | (278)           |
| Net amortization                 | 817  | 77              | 1,261           | 111             |
| <b>Net periodic benefit cost</b> | <b>\$ 968</b>                                | <b>\$ 676</b>   | <b>\$ 1,605</b> | <b>\$ 627</b>   |

|                                  | <b>Pension Benefits</b>                     |                 |                 |                 |
|----------------------------------|---|-----------------|-----------------|-----------------|
|                                  | <b>Nine Months Ended September 30, 2012</b> |                 | <b>2011</b>     |                 |
|                                  | <b>U.S.</b>                                 | <b>Non-U.S.</b> | <b>U.S.</b>     | <b>Non-U.S.</b> |
|                                  | <b>(In thousands)</b>                       |                 |                 |                 |
| Service cost                     | \$ 1,272                                    | \$ 1,006        | \$ 1,319        | \$ 620          |
| Interest cost                    | 3,051                                       | 1,632           | 3,380           | 1,756           |
| Expected return on plan assets   | (3,361)                                     | (773)           | (3,567)         | (837)           |
| Net amortization                 | 4,244                                       | 244             | 3,423           | 334             |
| <b>Net periodic benefit cost</b> | <b>\$ 5,206</b>                             | <b>\$ 2,109</b> | <b>\$ 4,555</b> | <b>\$ 1,873</b> |

|                                  | <b>Other Postretirement Benefits</b>         |               |   |                 |
|----------------------------------|--|---------------|---|-----------------|
|                                  | <b>Three Months Ended September 30, 2012</b> |               | <b>Nine Months Ended September 30, 2011</b> |                 |
|                                  | <b>2012</b>                                  | <b>2011</b>   | <b>2012</b>                                 | <b>2011</b>     |
|                                  | <b>(In thousands)</b>                        |               |   |                 |
| Service cost                     | \$ 191                                       | \$ 173        | \$ 572                                      | \$ 519          |
| Interest cost                    | 230  | 259           | 687   | 778             |
| Net amortization                 | (37)   | (39)          | (111)                                       | (117)           |
| <b>Net periodic benefit cost</b> | <b>\$ 384</b>                                | <b>\$ 393</b> | <b>\$ 1,148</b>                             | <b>\$ 1,180</b> |

The Company previously disclosed in its financial statements for the year ended December 31, 2011, that it expected to contribute approximately \$9.4 million to its pension plans and \$0.9 million to its other postretirement benefit plans in 2012. As of September 30, 2012,

\$8.1 million of contributions have been made to the pension plans and \$0.4 million have been made to its other postretirement benefit plans. The Company presently anticipates contributing up to an additional \$1.8 million in 2012 to fund its pension plans and other postretirement benefit plans.

**16. Legal Proceedings**

The Company is party to various legal proceedings arising in the ordinary course of business, none of which are expected to have a material adverse effect on its business, financial condition, results of operations or cash flows.



**Table of Contents**

**IDEX CORPORATION AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)**

**(unaudited)**

**17. Income Taxes**

The Company's provision for income taxes is based upon estimated annual tax rates for the year applied to federal, state and foreign income. The provision for income taxes increased to \$20.1 million in the third quarter of 2012 from \$14.8 million in the third quarter of 2011. The effective tax rate increased to 28.6% for the third quarter of 2012 compared to 23.4% in the third quarter of 2011 due to the mix of global pre-tax income among jurisdictions and a reversal of disallowed executive compensation expense in the prior year.

The provision for income taxes increased to \$65.4 million in the first nine months of 2012 from \$60.2 million in the same period of 2011. The effective tax rate increased to 29.5% for the first nine months of 2012 compared to 29.1% in the same period of 2011 due to the mix of global pre-tax income among jurisdictions, a reversal of disallowed executive compensation expense in the prior year and as a result of recent acquisitions.

The Company and its subsidiaries file income tax returns in the U.S. federal jurisdiction, and various state and foreign jurisdictions. Due to the potential for resolution of federal, state and foreign examinations, and the expiration of various statutes of limitation, it is reasonably possible that the Company's gross unrecognized tax benefits balance may change within the next twelve months by a range of zero to \$1.7 million.

**18. Subsequent Events**

On October 22, 2012, the Company's Board of Directors approved an increase in the authorized level for repurchases of common stock by \$200.0 million. The increased authorization will be added to the approximately \$50.0 million that remains available from the existing authorization approved by the Board of Directors in December 2011. Repurchases under the program will be funded with future cash flow generation.

---

**Table of Contents**

**Item 2. *Management's Discussion and Analysis of Financial Condition and Results of Operations.***

**Cautionary Statement Under the Private Securities Litigation Reform Act**

The Overview and Outlook and the Liquidity and Capital Resources sections of this management's discussion and analysis of financial condition and results of operations contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Exchange Act of 1934, as amended. These statements relate to, among other things, operating results and are indicated by words or phrases such as expects, should, will, and similar words or phrases. These expected statements are subject to inherent uncertainties and risks that could cause actual results to differ materially from those statements. The risks and uncertainties include, but are not limited to, IDEX Corporation's (IDEX or the Company) ability to integrate and operate acquired businesses on a profitable basis and other risks and uncertainties identified under the heading Risk Factors in item 1A of the Company's Annual Report on Form 10-K for the year ended December 31, 2011, and information contained in subsequent periodic reports filed by IDEX with the Securities and Exchange Commission. Investors are cautioned not to rely unduly on forward-looking statements when evaluating the information presented here.

**Overview and Outlook**

IDEX is an applied solutions company specializing in fluid and metering technologies, health and science technologies, and fire, safety and other diversified products built to customers specifications. IDEX's products are sold in niche markets to a wide range of industries throughout the world. Accordingly, its businesses are affected by levels of industrial activity and economic conditions in the U.S. and in other countries where IDEX does business and by the relationship of the U.S. dollar to other currencies. Levels of capacity utilization and capital spending in certain industries and overall industrial activity are among the factors that influence the demand for IDEX's products.

The Company has three reportable business segments: Fluid & Metering Technologies, Health & Science Technologies and Fire & Safety/Diversified Products. Within these three reportable segments, the Company maintains six strategic platforms, where we will primarily invest organically and through acquisitions, and seven groups, where we will primarily focus on organic growth to drive these high value diversified businesses. The Fluid & Metering Technologies segment is comprised of the Energy, Water and Waste Water, and Chemical, Food and Process ( CFP ) platforms as well as the Agricultural group. The Health & Science Technologies segment is comprised of the Optics & Photonics, Scientific Fluidics, and MPT platforms as well as the Containment and Industrial groups. The Fire & Safety/Diversified Products segment is comprised of the Dispensing, Rescue, Band-It, and Fire Suppression groups.

The Fluid & Metering Technologies segment designs, produces and distributes positive displacement pumps, flow meters, injectors, and other fluid-handling pump modules and systems and provides flow monitoring and other services for the food, chemical, general industrial, water and wastewater, agricultural and energy industries.

The Health & Science Technologies segment designs, produces and distributes a wide range of precision fluidics, rotary lobe pumps, centrifugal and positive displacement pumps, roll compaction and drying systems used in beverage, food processing, pharmaceutical and cosmetics, pneumatic components and sealing solutions, including very high precision, low-flow rate pumping solutions required in analytical instrumentation, clinical diagnostics and drug discovery, high performance molded and extruded, biocompatible medical devices and implantables, air compressors used in medical, dental and industrial applications, optical components and coatings for applications in the fields of scientific research, defense, biotechnology, aerospace, telecommunications and electronics manufacturing, laboratory and commercial equipment used in the production of micro and nano scale materials, precision photonic solutions used in life sciences, research and defense markets, and precision gear and peristaltic pump technologies that meet exacting original equipment manufacturer specifications.

## **Table of Contents**

The Fire & Safety/Diversified Products segment produces firefighting pumps and controls, rescue tools, lifting bags and other components and systems for the fire and rescue industry, and engineered stainless steel banding and clamping devices used in a variety of industrial and commercial applications, precision equipment for dispensing, metering and mixing colorants and paints used in a variety of retail and commercial businesses around the world.

Some of our key financial highlights for the nine months ended September 30, 2012 are as follows:

Sales of \$1.5 billion rose 8%; organic sales excluding acquisitions and foreign currency translation were up 4%.

Operating income of \$253.8 million increased 11%.

Net income increased 7% to \$156.6 million.

Diluted EPS of \$1.87 increased 12 cents.

We expect market conditions to remain challenging, particularly outside the US, resulting in expected fourth quarter flat organic revenue compared to the fourth quarter of 2011. Despite these challenging market conditions, our disciplined execution allows us to maintain our prior full year 2012 adjusted EPS guidance of \$2.65 - \$2.70.

## **Results of Operations**

The following is a discussion and analysis of our results of operations for the three and nine month periods ended September 30, 2012 and 2011. Segment operating income excludes unallocated corporate operating expenses. Certain prior year amounts have been revised to include the Dispensing Equipment segment as part of the Fire & Safety/Diversified Products segment and to reflect the movement of our Trebor business unit from the Health & Science Technologies segment to the Fluid & Metering Technologies segment.

In this report, references to organic sales, a non-GAAP measure, refers to sales from continuing operations calculated according to generally accepted accounting principles in the United States but excludes (1) sales from acquired businesses during the first twelve months of ownership and (2) the impact of foreign currency translation. The portion of sales attributable to foreign currency translation is calculated as the difference between (a) the period-to-period change in organic sales and (b) the period-to-period change in organic sales after applying prior period foreign exchange rates to the current year period. Management believes that reporting organic sales provides useful information to investors by helping identify underlying growth trends in our business and facilitating easier comparisons of our revenue performance with prior and future periods and to our peers. The Company excludes the effect of foreign currency translation from organic sales because foreign currency translation is not under management's control, is subject to volatility and can obscure underlying business trends. The Company excludes the effect of acquisitions because the nature, size, and number of acquisitions can vary dramatically from period to period and between the Company and its peers and can also obscure underlying business trends and make comparisons of long-term performance difficult.

Management's primary measurements of segment performance are sales, operating income, and operating margin. In addition, due to the highly acquisitive nature of the Company, the determination of operating income includes amortization of acquired intangible assets and, as a result, management reviews depreciation and amortization as a percentage of sales. These measures are monitored by management and significant changes in operating results versus current trends in end markets and variances from forecasts are analyzed with segment management.

**Table of Contents****Consolidated Results in the Three Months Ended September 30, 2012 Compared with the Same Period of 2011**

| (in thousands)   | Three Months Ended September 30, |            |
|--|----------------------------------|------------|
|  | 2012                             | 2011       |
| Net sales  | \$ 479,859                       | \$ 476,881 |
| Operating income   | 80,588                           | 71,305     |
| Operating margin   | 16.8%                            | 15.0%      |
| Depreciation and amortization                              | \$ 19,545                        | \$ 20,540  |
| Depreciation and amortization as a percentage of net sales | 4.1%                             | 4.3%       |

Sales in the three months ended September 30, 2012 were \$479.9 million, a 1% increase from the comparable period last year. This increase reflects a 1% increase in organic sales, 2% from acquisitions (ERC April 2012 and Matcon July 2012) and 2% unfavorable foreign currency translation. International sales represented approximately 49% of total sales in the current period compared with 53% in the same period in 2011.

For the third quarter of 2012, Fluid & Metering Technologies contributed 41% of sales and 45% of operating income; Health & Science Technologies accounted for 37% of sales and 29% of operating income; and Fire & Safety/Diversified Products represented 22% of sales and 26% of operating income.

Gross profit of \$194.8 million in the third quarter of 2012 increased \$13.3 million, or 7%, from 2011. Gross profit as a percent of sales, or gross margins, was 40.6% in the third quarter of 2012 and 38.1% in 2011. The increase in gross margin primarily resulted from an acquisition fair value inventory charge of \$12.8 million for CVI MG recorded in 2011.

Selling, general and administrative ( SG&A ) expenses decreased slightly to \$107.2 million in the third quarter of 2012 from \$107.3 million in 2011. The slight change reflects a decrease of approximately \$5.4 million from cost savings initiatives, partially offset by an increase of approximately \$2.6 million for incremental costs from new acquisitions and the absence of a \$2.7 million reduction in expense from CEO forfeited equity compensation recorded in 2011. As a percentage of sales, SG&A expenses were 22.3% for 2012 and 22.5% for 2011.

During the three months ended September 30, 2012, the Company recorded pre-tax restructuring expenses totaling \$7.1 million, while \$2.9 million was recorded for the same period in 2011. These restructuring expenses were mainly attributable to employee severance related to employee reductions across various functional areas, the termination of a defined benefit pension plan and facility rationalization resulting from the Company's cost savings initiatives.

Operating income of \$80.6 million in the third quarter of 2012 was up from the \$71.3 million recorded in 2011, primarily reflecting improved productivity and an acquisition fair value inventory charge for CVI MG recorded in 2011. Operating income as a percent of sales, or operating margin, of 16.8% in the third quarter of 2012 was up from 15.0% in 2011 primarily due to productivity and the acquisition fair value inventory charge for CVI MG recorded in 2011, partially offset by increased expenses from restructuring-related charges and the dilutive impact from acquisitions.

Other income, net was \$0.1 million in the third quarter of 2012 compared with a \$0.4 million expense recorded in 2011, primarily due to higher losses on foreign currency in 2011.

Interest expense increased to \$10.5 million in 2012 from \$7.8 million in 2011. The increase was principally due to higher debt levels issued in conjunction with the CVI MG acquisition and higher interest rates associated with converting the Revolving Facility debt to the fixed rate 4.2% Senior Notes.

**Table of Contents**

The provision for income taxes is based on estimated annual tax rates for the year applied to federal, state and foreign income. The provision for income taxes increased to \$20.1 million in the third quarter of 2012 compared to \$14.8 million in the third quarter of 2011. The effective tax rate increased to 28.6% for the third quarter of 2012 compared to 23.4% in the third quarter of 2011 due to the mix of global pre-tax income among jurisdictions and a reversal of disallowed executive compensation expense in the prior year.

Net income for the quarter of \$50.1 million increased from \$48.3 million in 2011. Diluted earnings per share in the third quarter of 2012 of \$0.60 increased \$0.02, or 3%, compared with 2011.

**Fluid & Metering Technologies Segment**

| (in thousands)   | Three Months Ended September 30, |            |
|--|----------------------------------|------------|
|  | 2012                             | 2011       |
| Net sales  | \$ 198,000                       | \$ 205,797 |
| Operating income   | 41,649                           | 40,883     |
| Operating margin   | 21.0%                            | 19.9%      |
| Depreciation and amortization                              | \$ 7,246                         | \$ 8,603   |
| Depreciation and amortization as a percentage of net sales | 3.7%                             | 4.2%       |

Sales of \$198.0 million decreased \$7.8 million, or 4%, in the third quarter of 2012 compared with 2011. This reflects a 1% decrease in organic sales and 3% unfavorable foreign currency translation. In the third quarter of 2012, organic sales decreased approximately 2% domestically and were flat internationally. Organic sales to customers outside the U.S. were approximately 48% of total segment sales during the third quarter of 2012, compared with 54% in 2011.

Sales within our Energy platform decreased compared to the third quarter of 2011 due to weakness in European markets caused by general economic conditions and warmer climate conditions, and a slowdown in liquid measurement projects. This was partially offset by strength in North American transportation end markets and in our distribution channel. Sales within our CFP platform decreased compared to the third quarter of 2011 on weak general industrial and chemical demand in our OEM and distributor channels in North America, Europe and China. Sales within our Water and Waste Water platform continues to experience ongoing municipal water end market softness in Europe and China. Sales within our Agricultural group increased compared to the third quarter of 2011, due to continued strong demand within this market.

Operating income and operating margin of \$41.6 million and 21.0%, respectively, were higher than the \$40.9 million and 19.9% recorded in the third quarter of 2011, primarily due to productivity and cost reduction initiatives, partially offset by slightly higher restructuring related charges.

**Health & Science Technologies Segment**

| (in thousands)   | Three Months Ended September 30, |            |
|--|----------------------------------|------------|
|  | 2012                             | 2011       |
| Net sales  | \$ 176,225                       | \$ 172,911 |
| Operating income   | 27,305                           | 19,287     |
| Operating margin   | 15.5%                            | 11.2%      |
| Depreciation and amortization                              | \$ 10,273                        | \$ 9,712   |
| Depreciation and amortization as a percentage of net sales | 5.8%                             | 5.6%       |

Sales of \$176.2 million increased \$3.3 million, or 2%, in the third quarter of 2012 compared with 2011. This reflects 7% growth from acquisitions (Matcon and ERC), partially offset by a 4% decrease in organic sales and

**Table of Contents**

1% unfavorable foreign currency translation. In the third quarter of 2012, organic sales increased 9% domestically and decreased 15% internationally. Organic sales to customers outside the U.S. were approximately 48% of total segment sales in the third quarter of 2012, compared with 54% in 2011.

Organic sales within our MPT platform decreased compared to the third quarter of 2011 due to weakness in the Asian food and pharmaceutical markets. Organic sales within our Scientific Fluidics platform were flat compared to the third quarter of 2011 due to market volatility on inconsistent OEM demand in North America. Sales within our Containment group decreased slightly compared to the third quarter of 2011 due to weak oil & gas distributor sales in European markets. Sales within our Optics and Photonics platform decreased compared to the third quarter of 2011 as we continue to experience weakness within the semiconductor, life science and defense markets. Sales within our Industrial group increased compared to the third quarter of 2011 due to higher distributor sales, partially offset by weakness in Europe and China.

Operating income of \$27.3 million in the third quarter of 2012 was up from the \$19.3 million recorded in 2011, primarily due to the \$12.8 million acquisition fair value inventory charge for CVI MG recorded in 2011 and cost savings from our prior period restructuring actions, partially offset by an increase in restructuring charges in 2012. Operating margin of 15.5% in the third quarter of 2012 was up from 11.2% in 2011, primarily due to the \$12.8 million acquisition fair value inventory charge for CVI MG recorded in 2011, partially offset by the dilutive impact from acquisitions and a \$2.7 million increase in restructuring charges.

**Fire & Safety/Diversified Products Segment**

| (in thousands)   | Three Months Ended |           |
|--|--------------------|-----------|
|  | September 30,      |           |
|  | 2012               | 2011      |
| Net sales  | \$ 108,199         | \$ 98,735 |
| Operating income   | 24,738             | 19,263    |
| Operating margin   | 22.9%              | 19.5%     |
| Depreciation and amortization                              | \$ 1,622           | \$ 1,844  |
| Depreciation and amortization as a percentage of net sales | 1.5%               | 1.9%      |

Sales of \$108.2 million increased \$9.5 million, or 10%, in the third quarter of 2012 compared with the third quarter of 2011. This reflects 13% organic growth offset by 3% unfavorable foreign currency translation. In the third quarter of 2012, organic sales increased 36% domestically and decreased 1% internationally. Organic sales to customers outside the U.S. were approximately 54% of total segment sales in the third quarter of 2012, compared with 61% in 2011.

Sales within our Dispensing group increased as a result of a large replenishment project in the North American market which began shipping in the second quarter of 2012, partially offset by weakness in European markets. The sales increase within our Band-It group was driven by general North American strength and product innovation, partially offset by weakness in Europe and the Middle East. Sales within our Fire Suppression group decreased as a result of weakness in European municipal fire markets, partially offset by growing sales in adjacent markets domestically and internationally. Sales within our Rescue group increased as a result of higher demand for our rescue tools within domestic markets, partially offset by shipment delays in Asia.

Operating income and operating margin of \$24.7 million and 22.9%, respectively, were higher than the \$19.3 million and 19.5% recorded in the third quarter of 2011, primarily due to improved productivity and cost reduction initiatives, partially offset by \$0.4 million higher restructuring charges in 2012 compared to 2011 within our Fire Suppression group.

**Table of Contents****Consolidated Results in the Nine Months Ended September 30, 2012 Compared with the Same Period of 2011**

| (in thousands)   | Nine Months<br>Ended<br>September 30, |              |
|--|---------------------------------------|--------------|
|  | 2012                                  | 2011         |
| Net sales  | \$ 1,463,420                          | \$ 1,357,768 |
| Operating income   | 253,807                               | 228,655      |
| Operating margin   | 17.4%                                 | 16.8%        |
| Depreciation and amortization                              | \$ 57,938                             | \$ 53,116    |
| Depreciation and amortization as a percentage of net sales | 4.0%                                  | 3.9%         |

Sales in the nine months ended September 30, 2012 were \$1,463.4 million, an 8% increase from the comparable period last year. This increase reflects a 4% increase in organic sales, 6% from acquisitions (AT Films January 2011, Microfluidics March 2011, CVI MG June 2011, ERC April 2012 and Matcon July 2012) and 2% unfavorable foreign currency translation. International sales represented approximately 51% of total sales in the period compared with 52% in 2011.

For the first nine months of 2012, Fluid & Metering Technologies contributed 42% of sales and 45% of operating income; Health & Science Technologies accounted for 36% of sales and 29% of operating income; and Fire & Safety/Diversified Products represented 22% of sales and 26% of operating income.

Gross profit of \$600.8 million in the first nine months of 2012 increased \$55.8 million, or 10%, from 2011. Gross margins were 41.1% in the first nine months of 2012 and 40.1% in 2011.

SG&A expenses increased to \$332.4 million in the first nine months of 2012 from \$313.5 million in 2011. The \$18.9 million increase reflects approximately \$26.3 million for incremental costs from new acquisitions, \$2.7 million for a benefit from CEO forfeited equity compensation recorded in 2011 and a \$2.8 million gain from the sale of a facility in Italy recorded in 2011, partially offset by a decrease of \$12.9 million from cost savings initiatives. As a percentage of sales, SG&A expenses were 22.7% for 2012 and 23.1% for 2011.

During the nine months ended September 30, 2012, the Company recorded pre-tax restructuring expenses totaling \$14.6 million, while \$2.9 million was recorded for the same period in 2011. These restructuring expenses were mainly attributable to employee severance related to employee reductions across various functional areas, the termination of a defined benefit pension plan and facility rationalization resulting from the Company's cost savings initiatives.

Operating income of \$253.8 million in the first nine months of 2012 was up from the \$228.7 million recorded in 2011, primarily reflecting an increase in volume and improved productivity. Operating margin of 17.3% in the first nine months of 2012 was up from 16.8% in 2011 primarily due to volume leverage and productivity, partially offset by increased expenses from restructuring-related charges and the dilutive impact from acquisitions.

Interest expense increased to \$31.7 million in 2012 from \$20.9 million in 2011. The increase was principally due to higher debt levels, issued in conjunction with the CVI MG acquisition, and higher interest rates associated with converting the Revolving Facility debt to the fixed rate 4.2% Senior Notes.

The provision for income taxes is based upon estimated annual tax rates for the year applied to federal, state and foreign income. The provision for income taxes increased to \$65.4 million for the first nine months of 2012 compared to \$60.2 in the same period in 2011. The effective tax rate increased to 29.5% for the first nine months of 2012 compared to 29.1% in the same period of 2011 due to the mix of global pre-tax income among jurisdictions, a reversal of disallowed executive compensation expense in the prior year and the impact of recent acquisitions.

**Table of Contents**

Net income for the current period of \$156.6 million increased from the \$146.5 million earned in 2011. Diluted earnings per share in the first nine months of 2012 of \$1.87 increased \$0.12, or 7%, compared with 2011.

**Fluid & Metering Technologies Segment**

| (in thousands)   | Nine Months Ended September 30, |            |
|--|---------------------------------|------------|
|  | 2012                            | 2011       |
| Net sales  | \$ 621,433                      | \$ 614,367 |
| Operating income   | 132,477                         | 124,221    |
| Operating margin   | 21.3%                           | 20.2%      |
| Depreciation and amortization                              | \$ 22,194                       | \$ 24,841  |
| Depreciation and amortization as a percentage of net sales | 3.6%                            | 4.1%       |

Sales of \$621.4 million increased \$7.1 million, or 1%, in the first nine months of 2012 compared with 2011. This reflects 3% organic growth and 2% unfavorable foreign currency translation. The increase in organic sales was largely attributed to growth across our Energy platform, CFP platform, and our Agricultural group. In the first nine months of 2012, organic sales increased approximately 4% domestically and 3% internationally. Organic sales to customers outside the U.S. were approximately 47% of total segment sales during the first nine months of 2012, compared with 46% in 2011.

Sales within our Energy platform increased compared to the first nine months of 2011, due to strong demand for systems used in upstream and downstream oil and gas applications both domestically and internationally. Additionally, large Energy project sales to emerging markets drove international sales growth, partially offset by weakness in the European downstream markets due to general economic conditions. Domestic sales growth within Energy was driven by the transportation end markets and strength in our distribution channel. Sales within our CFP platform increased compared to the first nine months of 2011 on strong general industrial and chemical demand in both our OEM and distributor channels in North America and Asia. In addition, CFP sales growth accelerated in emerging markets. Sales within our Agriculture group increased due to robust demand in North America. Offsetting the sales increases above was a decrease in sales within our Water and Waste Water platform, as the platform continues to experience ongoing municipal water end market softness due to municipal funding headwinds.

Operating income and operating margin of \$132.5 million and 21.3%, respectively, were higher than the \$124.2 million and 20.2% recorded in the first nine months of 2011, primarily due to volume leverage, productivity and benefits from prior period restructuring activities, partially offset by \$3.7 million of current period restructuring charges.

**Health & Science Technologies Segment**

| (in thousands)   | Nine Months Ended September 30, |            |
|--|---------------------------------|------------|
|  | 2012                            | 2011       |
| Net sales  | \$ 520,574                      | \$ 442,619 |
| Operating income   | 84,711                          | 75,653     |
| Operating margin   | 16.3%                           | 17.1%      |
| Depreciation and amortization                              | \$ 29,293                       | \$ 20,686  |
| Depreciation and amortization as a percentage of net sales | 5.6%                            | 4.7%       |

Sales of \$520.6 million increased \$78.0 million, or 18%, in the first nine months of 2012 compared with 2011. This reflects 19% growth from acquisitions (AT Films, Microfluidics, CVI MG, ERC and Matcon) and 1% unfavorable foreign currency translation. In the first nine months of 2012, organic sales increased 4% domestically and decreased 4% internationally. Organic sales to customers outside the U.S. were approximately 50% of total segment sales in the first nine months of both 2012 and 2011.



**Table of Contents**

Sales within our MPT platform increased compared to the first nine months of 2011 due a full nine months of sales from Microfluidics, acquired in March 2011, strength in Asian food and pharmaceutical markets, and large project orders received in the second half of 2011 which shipped during the first half of 2012. Sales within our Scientific Fluidics platform decreased compared to the first nine months of 2011 due to slowed instrumentation end markets driven by National Institutes of Health funding concerns, inventory reduction programs by our customers and inconsistent OEM demand in North America, partially offset by modest growth in the Life Sciences end market, particularly in Asia. Sales within our Containment group increased slightly compared to the first nine months of 2011 due to an increase in distributor sales and an upturn in the diesel and gas engine markets. Sales within our Optics and Photonics platform increased compared to the first nine months of 2011 primarily as a result of our CVI MG acquisition. However, 2012 sales within our Optics and Photonics platform are lower than anticipated due to weak demand in the defense, biotech and electronics end markets. Sales at our Industrial group decreased compared to the first nine months of 2011 due to lower sales to distributors and slower sales into automotive end markets.

Operating income of \$84.7 million in the first nine months of 2012 was up from the \$75.7 million recorded in 2011, primarily due to the \$12.8 million acquisition fair value inventory charge for CVI MG recorded in 2011 and productivity from prior period restructuring actions, partially offset by a \$5.4 million increase of restructuring costs in 2012. Operating margin of 16.3% in the first nine months of 2012 was down from 17.1% in 2011, due to the dilutive impact from acquisitions and current period restructuring charges.

**Fire & Safety/Diversified Products Segment**

| (in thousands)   | Nine Months Ended  |                    |
|--|--------------------|--------------------|
|  | September 30, 2012 | September 30, 2011 |
| Net sales  | \$ 328,173         | \$ 302,814         |
| Operating income   | 74,524             | 67,270             |
| Operating margin   | 22.7%              | 22.2%              |
| Depreciation and amortization                              | \$ 5,225           | \$ 6,561           |
| Depreciation and amortization as a percentage of net sales | 1.6%               | 2.2%               |

Sales of \$328.2 million increased \$25.4 million, or 8%, in the first nine months of 2012 compared with the first nine months of 2011. This reflects 12% organic growth and 4% unfavorable foreign currency translation. In the first nine months of 2012, organic sales increased 30% domestically and 1% internationally. Organic sales to customers outside the U.S. were approximately 57% of total segment sales in the first nine months of 2012, compared with 63% in 2011.

Sales within our Dispensing group increased on strength in our core North American markets and a large replenishment project, which began shipping in the second quarter of 2012. The sales increase within our Band-It group was driven by general North American industrial market improvement and strength in the oil and gas applications market. Sales within our Fire Suppression group increased as a result of geographic expansions into Eastern Europe and Asian markets and through the penetration into product adjacencies. Sales within our Rescue group increased as a result of robust demand for our rescue tools within emerging markets.

Operating income of \$74.5 million was higher than the \$67.3 million recorded in the first nine months of 2011, primarily due to volume leverage and productivity, partially offset by \$3.6 million of restructuring charges and a \$2.8 million gain on the sale of a facility in 2011. Operating margin of 22.7% in the first nine months of 2012 was up from 22.2% in 2011, primarily due to improved productivity and cost reduction initiatives, partially offset by current period restructuring charges and the gain on the sale of a facility in 2011.

**Liquidity and Capital Resources**

At September 30, 2012, working capital was \$549.8 million and the current ratio was 2.9 to 1. Cash flows from operating activities for the first nine months of 2012 increased \$64.9 million, or 37%, to \$240.5 million compared to the first nine months of 2011 mainly due to higher earnings and improved working capital.

---

**Table of Contents**

Cash flows provided by operating activities were more than adequate to fund capital expenditures of \$28.1 million and \$28.0 million in the first nine months of 2012 and 2011, respectively. Capital expenditures were generally for machinery and equipment that improved productivity, tooling, business system technology and replacement of equipment and facilities. Management believes that the Company has sufficient capacity in its plants and equipment to meet expected needs for future growth.

The Company maintains the Revolving Facility, which is a \$700.0 million unsecured, multi-currency bank credit facility expiring on June 27, 2016. At September 30, 2012, there were \$27.0 outstanding borrowings under the Revolving Facility and outstanding letters of credit totaled approximately \$7.1 million. The net available borrowing capacity under the Revolving Facility at September 30, 2012, was approximately \$665.9 million. Borrowings under the Revolving Facility bear interest, at either an alternate base rate or an adjusted LIBOR rate plus, in each case, an applicable margin. Such applicable margin is based on the Company's senior, unsecured, long-term debt rating and can range from .875% to 1.70%. Based on the Company's credit rating at September 30, 2012, the applicable margin was 1.05%. Interest is payable (a) in the case of base rate loans, quarterly, and (b) in the case of LIBOR rate loans, on the maturity date of the borrowing, or quarterly from the effective date for borrowings exceeding three months. An annual Revolving Facility fee, also based on the Company's credit rating, is currently 20 basis points and is payable quarterly.

On June 9, 2010, the Company completed a private placement of \$81.0 million (\$96.8 million) aggregate principal amount of 2.58% Series 2010 Senior Euro Notes due June 9, 2015 ( 2.58% Senior Euro Notes ) pursuant to a Master Note Purchase Agreement, dated June 9, 2010 (the Purchase Agreement ). The Purchase Agreement provides for the issuance of additional series of notes in the future, provided that the aggregate principal amount outstanding under the agreement at any time does not exceed \$750.0 million. The 2.58% Senior Euro Notes bear interest at a rate of 2.58% per annum, which is payable semi-annually in arrears on each June 9<sup>th</sup> and December 9<sup>th</sup> and will mature on June 9, 2015. The 2.58% Senior Euro Notes are unsecured obligations of the Company and rank pari passu in right of payment with all of the Company's other senior debt. The Company may at any time prepay all or any portion of the 2.58% Senior Euro Notes; provided that any such portion is greater than 5% of the aggregate principal amount of Notes then outstanding under the Purchase Agreement. In the event of a prepayment, the Company would be required to pay an amount equal to par plus accrued interest plus a make-whole premium. The Purchase Agreement contains certain covenants that restrict the Company's ability to, among other things, transfer or sell assets, create liens and engage in certain mergers or consolidations. In addition, the Company must comply with a leverage ratio and interest coverage ratio as set forth in the Purchase Agreement. The Purchase Agreement provides for customary events of default. In the case of an event of default arising from specified events of bankruptcy or insolvency, all outstanding 2.58% Senior Euro Notes will become due and payable immediately without further action or notice. In the case of payment events of defaults, any holder of the 2.58% Senior Euro Notes affected thereby may declare all the 2.58% Senior Euro Notes held by it due and payable immediately. In the case of any other event of default, a majority of the holders of the 2.58% Senior Euro Notes may declare all the 2.58% Senior Euro Notes to be due and payable immediately.

On December 6, 2010, the Company completed a public offering of \$300.0 million 4.5% senior notes due December 15, 2020 ( 4.5% Senior Notes ). The net proceeds from the offering of \$295.7 million, after deducting the \$1.6 million issuance discount, the \$1.9 million underwriting commission and \$0.8 million offering expenses, were used to repay \$250.0 million of outstanding bank indebtedness, with the balance used for general corporate purposes. The 4.5% Senior Notes bear interest at a rate of 4.5% per annum, which is payable semi-annually in arrears on each June 15<sup>th</sup> and December 15<sup>th</sup>. The Company may redeem all or a portion of the 4.5% Senior Notes at any time prior to maturity at the redemption prices set forth in the Note Indenture governing the 4.5% Senior Notes. The Company may issue additional debt from time to time pursuant to the Indenture. The Indenture and 4.5% Senior Notes contain covenants that limit the Company's ability to, among other things, incur certain liens securing indebtedness, engage in certain sale-leaseback transactions, and enter into certain consolidations, mergers, conveyances, transfers or leases of all or substantially all the Company's assets. The terms of the 4.5% Senior Notes also require the Company to make an offer to repurchase the 4.5% Senior Notes upon a change of control triggering event (as defined in the Indenture) at a price equal to 101% of their principal amount plus accrued and unpaid interest, if any.

---

**Table of Contents**

On December 9, 2011, the Company completed a public offering of \$350.0 million 4.2% senior notes due December 15, 2021 ( 4.2% Senior Notes ). The net proceeds from the offering of \$346.2 million, after deducting the \$0.9 million issuance discount, the \$2.3 million underwriting commission and \$0.6 million offering expenses, were used to repay \$306.0 million of outstanding bank indebtedness, with the balance used for general corporate purposes. The 4.2% Senior Notes bear interest at a rate of 4.2% per annum, which is payable semi-annually in arrears on each June 15<sup>th</sup> and December 15<sup>th</sup>. The Company may redeem all or a portion of the 4.2% Senior Notes at any time prior to maturity at the redemption prices set forth in the Note Indenture governing the 4.2% Senior Notes. The Company may issue additional debt from time to time pursuant to the Indenture. The Indenture and 4.2% Senior Notes contain covenants that limit the Company's ability to, among other things, incur certain liens securing indebtedness, engage in certain sale-leaseback transactions, and enter into certain consolidations, mergers, conveyances, transfers or leases of all or substantially all the Company's assets. The terms of the 4.2% Senior Notes also require the Company to make an offer to repurchase the 4.2% Senior Notes upon a change of control triggering event (as defined in the Indenture) at a price equal to 101% of their principal amount plus accrued and unpaid interest, if any.

On April 15, 2010, the Company entered into a forward starting interest rate contract with a notional amount of \$300.0 million with a settlement date in December 2010. This contract was entered into in anticipation of the issuance of the 4.5% Senior Notes and was designed to lock in the market interest rate as of April 15, 2010. In December 2010, the Company settled and paid this interest rate contract for \$31.0 million. The \$31.0 million is being amortized into interest expense over the 10 year term of the 4.5% Senior Notes, which results in an effective interest rate of 5.8%.

On July 12, 2011, the Company entered into a forward starting interest rate contract with a notional amount of \$350.0 million and a settlement date of September 30, 2011. This contract was entered into in anticipation of the issuance of the 4.2% Senior Notes and was designed to lock in the market interest rate as of July 12, 2011. On September 29, 2011, the Company settled this interest rate contract for \$34.7 million with a payment made on October 3, 2011. Simultaneously, the Company entered into a separate interest rate contract with a notional amount of \$350.0 million and a settlement date of February 28, 2012. The contract was entered into in anticipation of the expected issuance of the 4.2% Senior Notes and was designed to maintain the market rate as of July 12, 2011. In December 2011, the Company settled and paid the September interest rate contract for \$4.0 million, resulting in a total settlement of \$38.7 million. Of the \$38.7 million, \$0.8 was recognized as other expense in 2011 and the balance of \$37.9 million is being amortized into interest expense over the 10 year term of the 4.2% Senior Notes, which results in an effective interest rate of 5.3%.

There are two key financial covenants that the Company is required to maintain in connection with the Revolving Facility and 2.58% Senior Euro Notes. The most restrictive financial covenants under these debt instruments require a minimum interest coverage ratio of 3.0 to 1 and a maximum leverage ratio of 3.25 to 1. At September 30, 2012, the Company was in compliance with both of these financial covenants, as the Company's interest coverage ratio was 10.6 to 1 and the leverage ratio was 1.9 to 1. There are no financial covenants relating to the 4.5% Senior Notes or 4.2% Senior Notes.

On October 22, 2012, the Company's Board of Directors approved an increase in the authorized level for repurchases of common stock by \$200.0 million. The increased authorization will be added to the approximately \$50.0 million that remains available from the existing authorization approved by the Board of Directors in December 2011. Repurchases under the program will be funded with future cash flow generation. During the nine months ended September 30, 2012, 1.9 million shares were purchased at a cost of \$75.2 million.

The Company believes current cash and cash that will be generated from operations will be sufficient to meet its operating cash requirements, planned capital expenditures, interest on all borrowings, pension and postretirement funding requirements, authorized share repurchases and annual dividend payments to holders of the Company's stock for the remainder of 2012 and 2013. Additionally, in the event that suitable businesses are available for acquisition upon acceptable terms, the Company may obtain all or a portion of the financing for these acquisitions through the incurrence of additional borrowings. As of September 30, 2012, \$27.0 million is outstanding under the Revolving Facility.

---

**Table of Contents**

ASC 350 Goodwill and Other Intangible Assets requires that goodwill be tested for impairment at the reporting unit level on an annual basis and between annual tests if an event occurs or circumstances change that would more likely than not reduce the fair value of the reporting unit below its carrying value. Annually on October 31, goodwill and other acquired intangible assets with indefinite lives are tested for impairment. The Company concluded that the fair value of each of the reporting units was in excess of the carrying value as of October 31, 2011. The Company did not consider there to be any triggering event that would require an interim impairment assessment, therefore none of the goodwill or other acquired intangible assets with indefinite lives were tested for impairment during the three months ended September 30, 2012. However, if market conditions deteriorate, the Water reporting unit, the Optics and Photonics reporting unit and the CVI and Melles Griot trade names, could potentially be at risk for an impairment charge. As of September 30, 2012, the total goodwill balance of the Water and the Optics and Photonics reporting units was \$219.7 million and \$279.3 million, respectively. The total trade name balance for CVI MG as of September 30, 2012 is \$47.0 million.

**Item 3. *Quantitative and Qualitative Disclosures About Market Risk.***

The Company is subject to market risk associated with changes in foreign currency exchange rates and interest rates. The Company may, from time to time, enter into foreign currency forward contracts and interest rate swaps on its debt when it believes there is a financial advantage in doing so. A treasury risk management policy, adopted by the Board of Directors, describes the procedures and controls over derivative financial and commodity instruments, including foreign currency forward contracts and interest rate swaps. Under the policy, the Company does not use derivative financial or commodity instruments for trading purposes, and the use of these instruments is subject to strict approvals by senior officers. Typically, the use of derivative instruments is limited to foreign currency forward contracts and interest rate swaps on the Company's outstanding long-term debt.

The Company's foreign currency exchange rate risk is limited principally to the Euro, British Pound, Canadian Dollar and Chinese Renminbi. The Company manages its foreign exchange risk principally through invoicing customers in the same currency as the source of products. The effect of transaction gains and losses is reported within other income (expense)-net on the Consolidated Statements of Operations.

The Company's interest rate exposure is primarily related to the \$787.9 million of total debt outstanding at September 30, 2012. Approximately 5% of the debt is priced at interest rates that float with the market. A 50 basis point movement in the interest rate on the floating rate debt would result in an approximate \$0.2 million annualized increase or decrease in interest expense and cash flows. The remaining debt is fixed rate debt.

**Item 4. *Controls and Procedures.***

The Company maintains disclosure controls and procedures that are designed to ensure that information required to be disclosed in the Company's Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms, and that such information is accumulated and communicated to the Company's management, including its Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

As required by Rule 13a-15(b) promulgated under the Securities Exchange Act, the Company carried out an evaluation, under the supervision and with the participation of the Company's management, including the Company's Chief Executive Officer and the Company's Chief Financial Officer, of the effectiveness of the design and operation of the Company's disclosure controls and procedures as of the end of the period covered by this report. Based on the foregoing, the Company's Chief Executive Officer and Chief Financial Officer concluded as of September 30, 2012, that the Company's disclosure controls and procedures were effective.

There has been no change in the Company's internal controls over financial reporting during the Company's most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Company's internal controls over financial reporting.

**Table of Contents****PART II. OTHER INFORMATION****Item 1. Legal Proceedings.**

The Company and six of its subsidiaries are presently named as defendants in a number of lawsuits claiming various asbestos-related personal injuries, allegedly as a result of exposure to products manufactured with components that contained asbestos. These components were acquired from third party suppliers, and were not manufactured by any of the subsidiaries. To date, the majority of the Company's settlements and legal costs, except for costs of coordination, administration, insurance investigation and a portion of defense costs, have been covered in full by insurance, subject to applicable deductibles. However, the Company cannot predict whether and to what extent insurance will be available to continue to cover these settlements and legal costs, or how insurers may respond to claims that are tendered to them. Claims have been filed in jurisdictions throughout the United States. Most of the claims resolved to date have been dismissed without payment. The balance have been settled for various insignificant amounts. Only one case has been tried, resulting in a verdict for the Company's business unit. No provision has been made in the financial statements of the Company, other than for insurance deductibles in the ordinary course, and the Company does not currently believe the asbestos-related claims will have a material adverse effect on the Company's business, financial position, results of operations or cash flows.

The Company is also party to various other legal proceedings arising in the ordinary course of business, none of which is expected to have a material adverse effect on its business, financial condition, results of operations or cash flows.

**Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.**

The following table provides information about the Company's purchases of its common stock during the quarter ended September 30, 2012:

| <b>Period</b>                           | <b>Total Number<br/>of<br/>Shares Purchased</b> | <b>Average Price<br/>Paid<br/>per Share</b> | <b>Total Number<br/>of<br/>Shares Purchased as<br/>Part of Publicly<br/>Announced<br/>Plans<br/>or Programs<sup>(1)</sup></b> | <b>Maximum Dollar<br/>Value<br/>that May Yet<br/>be Purchased<br/>Under the Plans<br/>or Programs<sup>(1)</sup></b> |
|---|---|---|---|---|
| July 1, 2012 to July 31, 2012           | 130,320   | \$ 38.17                                    | 130,320   | \$ 83,947,153   |
| August 1, 2012 to August 31, 2012       | 855,972   | \$ 39.73                                    | 855,972   | \$ 50,149,089   |
| September 1, 2012 to September 30, 2012 | 8,168   | \$ 39.45                                    | 8,168   | \$ 49,826,828   |
| <b>Total</b>                            | <b>994,460</b>                                  | <b>\$ 39.51</b>                             | <b>994,460</b>  | <b>\$ 49,826,828</b>  |

(1) On October 22, 2012, the Company's Board of Directors approved an increase in the authorized level for repurchases of common stock by \$200.0 million. The increased authorization will be added to the approximately \$50.0 million that remains available from the existing authorization approved by the Board of Directors in December 2011, resulting in a total authorized repurchase amount of \$250.0 million.

**Item 6. Exhibits.**

The exhibits listed in the accompanying Exhibit Index are filed or furnished as part of this report.

**Table of Contents**

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

IDEX Corporation

By: /s/ HEATH A. MITTS

Heath A. Mitts

*Vice President and Chief Financial Officer*

*(Principal Financial Officer)*

By: /s/ MICHAEL J. YATES

Michael J. Yates

*Vice President and Chief Accounting Officer*

*(Principal Accounting Officer)*

November 2, 2012

**Table of Contents****EXHIBIT INDEX**

| <b>Exhibit</b> |  |
|----------------|--|
| <b>Number</b>  | <b>Description</b>   |
| 3.1            | Restated Certificate of Incorporation of IDEX Corporation (incorporated by reference to Exhibit No. 3.1 to the Registration Statement on Form S-1 of IDEX, et al., Registration No. 33-21205, as filed on April 21, 1988)  |
| 3.1(a)         | Amendment to Restated Certificate of Incorporation of IDEX Corporation (incorporated by reference to Exhibit No. 3.1(a) to the Quarterly Report of IDEX on Form 10-Q for the quarter ended March 31, 1996, Commission File No. 1-10235)  |
| 3.1(b)         | Amendment to Restated Certificate of Incorporation of IDEX Corporation (incorporated by reference to Exhibit No. 3.1(b) to the Current Report of IDEX on Form 8-K dated March 24, 2005, Commission File No. 1-10235)   |
| 3.2            | Amended and Restated By-Laws of IDEX Corporation (incorporated by reference to Exhibit No. 3.1 to the Current Report of IDEX Corporation on form 8-K filed November 14, 2011, Commission File No. 1-10235)   |
| 31.1           | Certification of Chief Executive Officer Pursuant to Section 302 of Sarbanes Oxley Act of 2002   |
| 31.2           | Certification of Chief Financial Officer Pursuant to Section 302 of Sarbanes Oxley Act of 2002   |
| 32.1           | Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350  |
| 32.2           | Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350  |
| 101            | The following financial information from IDEX Corporation's Quarterly Report on Form 10-Q for the quarter ended September 30, 2012, formatted in XBRL includes: (i) the Condensed Consolidated Balance Sheets, (ii) the Condensed Consolidated Statements of Earnings, (iii) the Condensed Consolidated Statements of Comprehensive Income, (iv) the Condensed Consolidated Statement of Shareholders' Equity, (v) the Condensed Consolidated Statements of Cash Flows, and (vi) Notes to the Condensed Consolidated Financial Statements. |